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ABSTRACT 
Inflammation is involved in the pathogenesis of many different disorders, 
including glomerulonephritis, fibrosis and cancer. Unraveling the regulatory 
mechanisms underlying the molecular processes of inflammation remains 
crucial for the development of novel therapeutics for future treatment of 
inflammatory disorders.  
Sphingosine 1-phosphate (S1P) is a bioactive sphingolipid molecule, 
which likely plays an important role in inflammation. However, the molecular 
mechanisms involved in S1P-mediated inflammation are still not completely 
understood. This work aimed to unravel the interconnection between S1P and 
other molecular players implicated in inflammatory response, as well as to 
indicate the S1P receptor subtype the activation of which contributes to 
proliferation and migration of non-cancerous cells and to metastatic progression 
of breast cancer. In addition, the therapeutic potential of drugs targeting early 
steps of the inflammatory response was assessed.  
As model systems for the non-cancerous studies we used renal mesangial 
cells (rMC) and mouse embryonic fibroblasts (MEF), and for the cancer studies 
the breast cancer cell line MDA-MB-231 and two metastatic sublines derived 
from lung (4175) and bone (1833).  
Our data demonstrate that the S1P3 receptor is strongly upregulated in 
lung and bone metastatic cell lines compared to the parental MDA-MB-231 
cells, and its activation by S1P has pro-inflammatory, pro-migratory and pro-
invasive potential by inducing COX-2 expression and PGE2 signaling via EP2 
and EP4. These data were confirmed in non-cancerous studies, where we found 
that S1P3 receptor is upregulated in mMC and MEFs upon the loss of SphK2. 
Our results show that the deficiency of SphK2 in these cells correlates with an 
enhanced proliferative and migratory capacity, indicating that SphK2 exerts 
suppressive effects on cell growth and migration. This finding is likely to be due 
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to the enhanced expression of S1P3, as its depletion in mesangial cells reduced 
their proliferation and migration rate. 
Our next study revealed that the novel cPLA2 inhibitors AVX001 and 
AVX002 have an anti-inflammatory potential in cultures of rMC by reducing 
the pro-inflammatory mediator PGE2 through the inhibitory effect on NFκB 
activation. Thus, they represent promising novel drugs for the treatment of 
inflammatory disorders.  
Altogether, our data demonstrate for the first time a critical role of the 
S1P3 receptor in S1P-mediated proliferative and inflammatory responses, and 
identify S1P3 as a potential target for therapeutic intervention to treat 
inflammation-associated proliferative disorders. 
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ABBREVIATIONS 
 
AA  arachidonic acid 
ABC  ATP-binding cassette 
Akt/PKB protein kinase B 
BSA  bovine serum albumin  
C1P  ceramide 1-phosphate 
CNS  central nervous system  
COX  cyclooxygenase 
CTGF connective tissue growth factor  
DMEM Dulbecco’s modified Eagle’s medium 
EDG  endothelial differentiation genes  
EGFR epidermal growth factor receptor 
EP  E prostanoid receptors 
ER  endoplasmic reticulum 
ER+/-  estrogen receptor positive/negative  
GN  glomerulonephritis 
ERK  extracellular regulated kinase 
G-protein     guaninenucleotide binding proteins 
GPCRs G-protein-coupled receptors 
IL-1ȕ  interleukin-1ȕ 
IP3  inositol triphosphate 
IUPHAR International Union of Basic and Clinical Pharmacology 
JNK  c-jun N-terminal kinases 
kDa  kilo Dalton 
LPA  lysophosphatidic acid  
MAPK mitogen-activated protein kinase 
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MEFS mouse embryonic fibroblasts 
NF-κB nuclear factor kappa-light-chain-enhancer of activated B cells 
PAI-1  plasminogen-activator inhibitor  
PBS  phosphate buffered saline 
PDGF platelet-derived growth factor 
PGs  prostaglandins 
PGE2  prostaglandin E2 
PKC  protein kinase C 
cPLA2 cytosolic phospholipase A2 
iPLA2 calcium-independent phospholipase A2 
sPLA2 secretory phospholipase A2 
PLC  phospholipase C 
cPGES cytosolic prostaglandin E synthase 
mPGES microsomal prostaglandin E synthase 
SDS-PAGE sodium dodecylsulfate-polyacrylamide gel electrophoresis 
S1P  sphingosine-1 phosphate 
S1PRs sphingosine-1 phosphate receptors 
SM  sphingomyelin 
SMases sphingomyelinases 
SPAK stress-activated protein kinase signaling complex 
SphK (SK) sphingosine kinase 
STAT3 signal transducer and activator of transcription 3 
TNF-α tissue necrosis factor α 
uPAR  urokinase-type plasminogen activator receptor 
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1.1. Introduction to sphingolipids 
Sphingolipids were first time described in 1884 by the German surgeon 
Johann Ludwig Wilhelm Thudichum who isolated a variety of novel lipid 
species from brain extracts. Due to the enigmatic nature and the riddle of the 
functions, the smallest molecule in this group was named “sphingosine” after 
the Sphinx in Greek mythology [1]. The broader term “sphingolipids” was 
proposed later by Carter et al. [2] for all lipids which derive from sphingosine. 
Over the last century, a large number of sphingolipid subspecies have been 
isolated and characterized. 
1.1.1. Chemical structure of sphingolipids 
Sphingolipids are amphipathic molecules with both hydrophobic and 
hydrophilic properties. The hydrophobic part is represented by the sphingoid 
base, a long-chain amino alcohol of 18 – 20 carbon atoms, and a fatty acid 
coupled through an amide bond at C2 position, whereas the hydrophilic part is 
represented by the head group. The diversity of sphingolipid species is the result 
of structural variations in the backbones, in the attached fatty acids and the head 
groups (Fig. 1).  
Sphingosine (sphinganine) is the prevalent backbone of all mammalian 
sphingolipids, although various other long-chain bases are also known, mainly 
characterized by different alkyl chain lengths, positions of double bonds 
(sphingadienes), degrees of saturation (the saturated form of sphingosine is 
sphinganine) and degrees of hydroxylation (phytosphingosine). Free sphingoid 
bases are typically present in very small amounts, most of them are amide-
linked to fatty acid [3].  
The N-acetylated sphingoid bases lacking additional head groups, 
generally termed “ceramides”, are precursors for all complex sphingolipids. 
Depending on the backbone, ceramides are subclassified into dihydroceramide 
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(derivatized from sphinganine), ceramide (backbone – sphingosine) or 
phytoceramide (backbone – phytosphingosine). Fatty acid chains are usually 14 
– 36 carbon atoms in length and saturated, with a single double bond or a 
hydroxyl group, although there are also many variations of acyl chain 
composition. Ceramide  plays an important role as a signaling molecule or can 
be converted to higher sphingolipids by addition of a hydrophilic head group at 
the sphingoid C1 hydroxyl group [4,5]. For instance, the transfer of 
phosphocholine yields sphingomyelin (SM) by the action of SM synthase, or the 
 
 
 
 
 
 
Fig. 1. Basic structure and classification of sphingolipids [6]. 
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transfer of sugar residues to yield glycosphingolipids, including gangliosides 
and sulfatides [7].  
There is also a small number of lyso-sphingolipids existing, such as 
sphingosine 1-phosphate (S1P), sphingosine 1-phosphocholine 
(lysosphingomyelin) and lyso-glycosphingolipids. Of these lyso-sphingolipids, 
only S1P has been extensively characterized so far. The functions or regulations 
of lysosphingomyelin and lyso-glycosphingolipids are still poorly understood. 
1.1.2. The sphingolipid biosynthesis 
The generation and degradation of sphingolipids is regulated by 
interconnected metabolic pathways. All sphingolipids originate from the same 
de novo synthesis pathway starting at the cytosolic leaflet of the endoplasmic 
reticulum with the  condensation of L-serine and palmitoyl CoA by action of 
serine palmitoyltransferase, and yielding 3-keto-dihydrosphingosine [8,9]. In 
turn, 3-keto-dihydrosphingosine is reduced to dihydrosphingosine (sphinganine) 
and subsequently acylated  by (dihydro) ceramide synthases resulting in the  
production of dihydroceramide [10]. Ceramides are formed by desaturation of 
dihydroceramide [11] and can further be either phosphorylated by ceramide 
kinase to C1P [12], glycosylated by glucosyl- or galactosyl ceramide synthases 
to form glycosphingolipids [13] or converted back to SM by the action of SM 
synthases [14].  
The breakdown of complex sphingolipids back to ceramide takes place in 
the lysosomes and is catalyzed by specific hydrolases, which all possess a pH 
optimum in the acidic range. The final steps are carried out by a glucosidase 
from glucosylceramide, galactosidase from galactosylceramide or an acid 
SMase from SM [15].  Ceramide can be further deacetylated by a lysosomal 
acid ceramidase leading to the formation of sphingosine [16]. Sphingosine is the 
only species which is able to exit the lysosome and thereby can feed into the de 
novo pathway or serve as a substrate for two sphingosine kinases (SphKs) [17]. 
Chapter 1. General introduction 
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The product, sphingosine 1-phosphate (S1P), can be converted back to 
sphingosine by the action of specific S1P phosphatases (SPP1 and SPP2) and 
unspecific phosphate phosphatases [18,19]. It can also be irreversibly degraded 
by the enzyme S1P lyase to non-sphingolipid products, phosphoethanolamine 
and hexadecenal [20].  
Sphingolipids are essential components of eukaryotic cell membranes and 
comprise ~ 10 – 20% of membrane lipids, thereby executing important 
structural roles in the regulation of the membrane fluidity and subdomain 
structure of the lipid bilayer [5]. Furthermore, a multitude of studies on 
sphingolipid metabolism and action have been performed during the last 
decades now revealing that certain subspecies, most importantly ceramide, 
sphingosine, S1P and C1P, also act as intercellular and intracellular signaling 
molecules.  
1.1.3. The cellular sphingolipid rheostat  
Ceramide, sphingosine and S1P are considered as critical mediators of cell 
survival and death. Based on the findings that ceramide and sphingosine induce 
cell growth arrest and apoptosis [21], whereas S1P rather mediates cell 
proliferation and survival [22], and that these two molecules are inter-
convertible within the cells, the term “sphingolipid rheostat” was proposed [23]. 
According to this concept, the dynamic balance between ceramide/sphingosine 
and S1P regulates the cell’s fate in response to different stimuli [24,25].  
Many studies so far have presented evidence that ceramide is an important 
second messenger in various stress responses and plays a crucial role in cell 
death [21,26,27]. Different stress stimuli like TNFα, Ȗ-interferon, interleukin-
1ȕ, UV light, doxorubicin, etc., induce the formation of ceramide through the 
activation of either SMase or de novo synthesis [27,28]. In turn, ceramide can 
directly affect a variety of enzymes involved in stress signaling cascades, 
including protein kinase C (PKC) isoenzymes [29,30], c-Raf [31], cPLA2 [32], 
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KSR [33], cathepsin D [34] and protein phosphatases (PP1 and PPA2) [35,36]. 
It has also been shown that ceramide can induce apoptosis in cells by the 
mitochondrial pathway [37]. For instance, ceramide-associated inhibition of the 
PI3K/Akt pathway and ceramide-induced activation of cathepsin D leads to 
dephosphorylation of pro-apoptotic Bcl-2 family members Bad and Bid, 
respectively, and activation of apoptotic pathways in mitochondria [34,38]. 
Therefore, ceramide accumulation mediates mitochondrial outer membrane 
permeabilization by regulating different Bcl-2 members by various 
mechanisms.  
Sphingosine has been attributed both growth promoting and growth 
inhibiting or apoptotic effects, which seems to depend on the cellular activity of 
SphKs to convert sphingosine to the growth promoting S1P or on a direct effect 
of sphingosine’s molecular targets, such as PKC isoenzymes [39]. However, the 
detailed mechanisms of sphingosine-mediated cell death are still unclear. A 
recent study showed that sphingosine interacts with the pro-survival adaptor 
protein 14-3-3 and allows phosphorylation of this molecule by protein kinase A 
(PKA) and PKCδ, therefore blocking an important pro-survival pathway [40].  
The effects of ceramide and sphingosine could be attenuated by an increase 
of S1P production, which has been associated with cell proliferation and 
survival [22,23,41]. Therefore, the agents that regulate the conversion of 
ceramide/sphingosine to S1P may play a crucial role in cell fate. Two isoforms 
of SphKs, which catalyze the synthesis of S1P from sphingosine and denoted 
SphK1 and SphK2, have been discovered and partially characterized [42,43]. 
Although both of these enzymes use the same substrate to produce the same 
product, they have different subcellular localizations and are hypothesized to 
exert differential cellular activity. For example, SphK1 promotes cell growth, 
whereas SphK2 rather triggers cell death. SphK1, but not SphK2, has emerged 
as a critical regulator of the sphingolipid rheostat. Indeed, as a consequence of 
SphK1 inhibition, not only cellular  S1P levels decrease, but also cellular  
Chapter 1. General introduction 
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ceramide levels increase, which may then reprogram cells towards  cell death 
[44].  
Given this key role of sphingolipids in regulating cell proliferation and 
survival, it has been suggested that the sphingolipid rheostat is dysregulated in 
proliferative disorders, including cancer, glomerulonephritis, and fibrosis. In 
these diseases,  SphK1 was shown to be upregulated and to overproduce the 
pro-survival factor S1P [45–48].  
1.1.4. Sphingosine 1-phosphate – a specific ligand for G-protein 
coupled receptors 
Sphingosine 1-phosphate (2S-amino-1-(dihydrogen phosphate)-4E-
octadecene-1,3R-diol) is a key bioactive molecule which regulates various 
biological and pathophysiological cellular responses (Fig. 2) [49]. Many studies 
point to an intracellular role for S1P, where it acts as a second messenger by 
binding to several proteins and regulating their functions. For instance, it has 
recently been suggested that nuclei contain a high amount of S1P, which 
regulates gene transcription by inhibiting histone deacetylases [50]. In addition, 
S1P can act as a missing cofactor for activation of NF-κB pathway [51], 
mediate cytochrome-c oxidase assembly and respiration in mitochondria and 
induce cellular inhibitor of apoptosis (cIAP2) [52]. However, the majority of 
important biological effects are known to be mediated by extracellular S1P. 
Accumulating evidence now suggests a  contribution of extracellular S1P to 
diseases associated with inflammation, proliferation and resistance to apoptosis 
[53–56], which makes it an attractive target in biomedical research. 
The concentration of S1P in the blood and lymph plasma is high and 
reaches micromolar ranges, whereas S1P concentration in tissues is low, 
creating a S1P gradient [57]. For many years, it was assumed that blood 
platelets represent the main source of plasma S1P [58]. However, clear new data 
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have recently been reported that erythrocytes and, to some extent, also 
endothelial cells are the major sources of plasma S1P [59,60].  
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2. Schematic representation of cellular processes regulated by intracellular 
and extracellular S1P [61].  
 
Little is known about the molecular mechanisms by which S1P is secreted 
into the extracellular environment. Since S1P has a polar head group and cannot 
pass the cell membrane, it requires the activity of a transporter system to reach 
the extracellular space from its intracellular site of synthesis. The ATP-binding 
cassette (ABC) family of transporters was first identified in vitro to be involved  
in S1P export [62]. However, the relevance of these transporters in S1P export 
has been questioned, since ABC knockout mice showed no phenotype of S1P 
distribution, which suggests the existence of other S1P-transporters. Indeed, 
recently the spinster homolog 2 (Spns2) was recognized as a unique type of S1P 
transporter [63]. Although, Spns2 appears to be the main S1P exporter in 
endothelial cells based on the in vitro and in vivo data, other studies showed that 
it is not involved in S1P release from platelets and erythrocytes [64], raising the 
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possibility that Spns2 is not the only regulator of the plasma S1P concentration 
[65].  
Outside the cell S1P acts in an autocrine and paracrine manner as a ligand 
for specific G protein-coupled receptors, named S1P receptors (S1PRs) [66]. 
These receptors were originally named endothelial differentiation genes (EDG), 
based on the first detected member of the family, EDG-1, which was identified 
in vitro as an inducible transcript of endothelial cell differentiation [67]. So far, 
eight receptor subtypes have been described. Although, the later discovered 
receptors of this family have no involvement in endothelial differentiation, they 
were characterized based on their sequence similarity. With the identification of 
S1P as a high affinity ligand for EDG-1 [68] the classification was formalized. 
Today the IUPHAR has renamed these EDG receptors to S1P receptors (S1P1-5) 
and LPA receptors (LPA1-3), according to their main physiological ligand and 
the chronological order of discovery within the family [69].  
There are currently five bona fide cognate GPCRs for S1P (S1P1-5, 
formerly, EDG-1, -5, -3, -6, -8 respectively). A specific repertoire of S1P 
receptors expression in different organs and tissues, and their individual ability 
to couple different G proteins (guanine nucleotide binding proteins) (αi, αq or 
α12/13) with subsequent activation of corresponding downstream signaling 
pathways designate the diversity of S1P-mediated effects. Over the last years a 
tremendous progress has been made in understanding the properties and 
functions of the S1PRs family (Table 1.1.). However, the molecular players 
involved in S1PRs signaling and the cellular responses triggered by these 
receptors are still not fully understood. The complexity of S1P binding and 
activating different S1PR subtypes that couple to a variety of G proteins that 
finally leads to either additive effects or neutralizing effects, underscore the 
need for further investigation. Indeed, studies, which address the possible role 
of S1PRs in the development of different diseases, may provide novel 
therapeutic targets.  
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Table 1.1. S1P receptors and their biological effects 
Receptor Main tissue 
distribution  
G protein Downstream 
signaling 
Cellular responses 
S1P1 Ubiquitous  Gi/o 
Rho 
Rac↑ 
ERK1/β↑  
PIγK/Akt↑ 
 AC↓ 
Migration↑, 
proliferation↑, 
survival↑, cell-cell 
contacts, 
angiogenesis↑, 
lymphocyte 
trafficking  
S1P2 Ubiquitous Gi/o 
Gq 
G12/13 
Rac↓ 
Rho↑ 
PLC↑ 
[Ca2+]i↑  ERK1/β↑ 
JNK↑  
pγ8↑ 
Migration↓, 
contribution to 
vascular 
development, pro-
apoptotic signaling 
S1P3 Ubiquitous Gi/o 
Gq 
G12/13  Rho↑ 
Rac↑ 
PLC↑  
[Ca2+]i↑ ERK1/β↑  
Akt↑ 
Heart rate↓, 
migration↑, 
proliferation↑, 
survival↑, 
contribution to 
vascular 
development 
S1P4 Lymphoid 
tissue and 
hematopoietic 
cells 
Gi/o  
G12/13 Rho↑↓ 
PLC↑  
[Ca2+]i↑  ERK1/β↑  
Cdc4β↑  
AC↑ 
Migration↑↓, 
cytoskeleton 
rearrangement 
S1P5 CNS, NK 
cells, spleen 
and skin  
Gi/o 
G12 
ERK1/β↓ 
AC↓  
p54↑ 
JNK↑ 
Proliferation↓, brain 
myelinization 
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1.2.  Inflammation 
Inflammation is an important cellular response triggered by various 
mechanical, chemical or immunological stress factors and characterized by 
symptoms of pain, fever, redness, swelling and loss of function. It represents a 
complex of events starting with an initial production of pro-inflammatory 
mediators which recruit professional inflammatory cells to the site of injury to 
dispose the offending trigger [70]. Inflammation is now recognized as a 
hallmark of various diseases, including arthritis, kidney disorders 
(glomerulonephritis, fibrosis, acute kidney injury) and cancer therefore, 
understanding the inflammation cascade is mandatory for the development of 
new treatments.  
1.2.1. Eicosanoids production pathway 
Eicosanoids (prostaglandins, thromboxanes and leukotrienes) are crucial 
players in inflammation which directly contribute to the symptoms of various 
diseases. The formation of arachidonic acid (AA) is catalyzed by a superfamily 
of PLA2 enzymes, including secretory PLA2 (sPLA2), Ca2+-independent PLA2 
(iPLA2) and cytosolic PLA2 (cPLA2) [71]. Among this group, especially the 
group IVA cPLA2 shows selectivity for AA-containing phospholipids and, 
therefore, represent critical enzymes in the regulation of eicosanoids synthesis 
[72]. Activation of cPLA2 by Ca2+ and MAPK leads to its translocation from the 
cytosol to the plasma membrane, where it liberates AA from the phospholipids. 
The subsequent conversion of AA is mediated either by cyclooxygenases 
(COXs) to generate prostaglandins (PGs) and thromboxanes or by 
lipoxygenases to generate leukotrienes. Two COX isoforms exist, i.e. the 
constitutively expressed COX-1 and the inducible COX-2. Whereas COX-1 
produces low levels of PGs for physiological purposes, COX-2 is considered to 
be induced under inflammatory conditions and to contribute to the high levels of 
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PGE2 in inflammation. COXs catalyze the conversion of AA into the unstable 
intermediate metabolite PGG2, which is subsequently reduced to PGH2 – a 
precursor for different PGs (PGI2, PGD2, PGF2α, PGE2 and thromboxane A2). 
Once synthesized, PGH2 is rapidly converted into prostanoids by the action of 
specific prostaglandin synthases. There are three particular synthases, which 
contribute to PGE2 synthesis: microsomal PGE synthase-1 (mPGES-1), 
microsomal PGE synthase-2 (mPGES-2) and cytosolic PGE synthase (cPGES) 
[73]. mPGES-1 is frequently induced concomitantly with COX-2 by various 
inflammatory stimuli to generate a rapid increase of PGE2 production, while 
mPGES-2 and cPGES are constitutively expressed and functionally coupled to 
COX-1 to maintain physiological levels of PGE2 [74]. Induction of COX-
2/mPGES-1 leads to the production of PGE2, which uniquely signals via four 
specific GPCRs, named E prostanoid receptors (EP1-4), and thus plays a major 
role in inflammation [75]. 
1.2.2. Implication of molecular players of inflammation in multiple  
disorders  
The contribution of PGE2 to inflammation has been demonstrated in many 
studies, all confirming the role of this lipid in inflammation-associated diseases. 
However,  mPGES-1-/- mice are protected from a variety of inflammatory 
diseases, like collagen-induced arthritis and antigen-induced paw edema [76]. 
Based on these findings, targeting mPGES-1 has been considered as a possible 
therapeutic approach. mPGES1 is overexpressed in different types of cancers, 
including lung cancer and cervical cancer and its overexpression in 
experimental models promotes tumor growth, metastasis, angiogenesis and 
resistance to chemotherapy. Knockdown of mPGES-1 reduced PGE2 synthesis, 
cell proliferation and invasion of  Levis lung carcinoma cells in vitro and also 
reduced xenograft formation in mice in vivo, while its overexpression has the 
opposite effect [77].  
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Another enzyme essential for PGE2 synthesis, COX-2, also contributes to 
cancer progression. Sustained induction of COX-2 expression promotes the 
transition from acute to chronic inflammation, which is a hallmark of 
carcinogenesis. Systemic inflammation facilitates tumor growth and metastasis 
by altering the tumor cell phenotype and activating stromal cells to generate a 
pro-tumorogenic microenvironment. Overexpression of COX-2 is found in 
many types of cancer, including lung, colon, breast, gastric and pancreas, and 
associated with poor prognosis and shorter overall survival [78–80]. There are 
several mechanisms underlying the carcinogenic activity of COX-2. Activation 
of COX-2/PGE2 pathway induces proliferation of cancer cells [81], and also 
prevents apoptosis, thereby mediating resistance to chemotherapy [82]. Another 
mechanism is based on the pro-angiogenic activity of COX-2 [83]. Data from 
several studies suggest that expression of COX-2 in breast and lung cancer cells 
upregulates vascular endothelial growth factor C (VEGF-C), which, via VEGF 
receptor 3, promotes lymphoangiogenesis [84]. Furthermore, COX-2 expression 
can increase the migratory and invasive phenotype of cancer cells and is tightly 
linked to lymph node metastasis. Inhibition of COX-2 by the selective inhibitor 
celecoxib decreased tumor growth and metastasis in a xenograft model of breast 
cancer [85]. Involvement of the COX-2/mPGES-1/PGE2 cascade  was also 
demonstrated in models of kidney toxicity, such as an acute cisplatin-induced 
kidney injury in renal parenchymal cells [86]. Moreover, TGFȕ triggered 
activation of the COX-2/mPGES-1 cascade, leads to increased formation of  
PGE2, which, in turn,  promotes proliferation of mouse mesangial cells via the 
EP1 receptor [87].  
An alternative target for the treatment of inflammatory disorders is the 
upstream located cPLA2 as it catalyzes the rate-limiting step in the generation of 
PGE2. In a chronic ear edema  model in mice, an inhibitor of cPLA2, 
AACOCF3, exerted a  suppressive effect on PMA-induced  ear edema [88]. 
Furthermore,  cPLA2 inhibitors  attenuated ischemia/reperfusion-induced lung 
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injury [89]. Additionally, in a mouse model of multiple sclerosis, the 
experimental autoimmune encephalomyelitis (EAE), which represents an 
inflammatory demyelinating disease, it was shown that the cPLA2 inhibitor 
AACOCF3 significantly reduces symptoms of EAE, indicating a role of PLA2 in 
the pathogenesis of multiple sclerosis [90]. 
Taken together, these data suggest that PGE2 synthesis is involved in 
numerous acute and chronic inflammation processes and that pharmacological 
interference in different steps of PGE2 generation may be beneficial for treating 
inflammatory diseases. 
 Aim of the thesis 
The aim of this thesis was to study the interconnection between the two 
lipid molecules S1P and PGE2, and their contribution to proliferation and 
migration of non-cancerous cells associated with proliferative disorders 
(mesangial cells, embryonic fibroblasts), and of metastatic breast cancer cells. 
Another focus was to investigate the role of the bioactive sphingolipid molecule 
S1P in inflammation-associated diseases, and to identify the S1P receptor 
subtype involved in S1P signaling as a potential target to prevent these 
disorders. In addition, the mechanisms of regulation of inflammation were 
elucidated using pharmacological modulators targeting this signaling pathway. 
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Abstract 
Breast cancer is one of the most common and devastating malignancy 
among women worldwide. Recent evidence suggests that malignant progression 
is also driven by processes involving the sphingolipid molecule sphingosine 1-
phoshate (S1P) and its binding to cognate receptor subtypes on the cell surface. 
To investigate the effect of this interaction on the metastatic phenotype, we used 
the breast cancer cell line MDA-MB-231 and the sublines 4175 and 1833 
derived from lung and bone metastases in nude mice, respectively. In both 
metastatic cell lines expression of the S1P3 receptor was strongly upregulated 
compared to the parental cells and correlated with higher S1P-induced 
intracellular calcium ([Ca2+]i), higher cyclooxygenase (COX)-2 and microsomal 
prostaglandin (PG) E2 synthase expression, and consequently with increased 
PGE2 synthesis. PGE2 synthesis was decreased by antagonists and siRNA 
against S1P3 and S1P2. Moreover, in parental MDA-MB-231 cells 
overexpression of S1P3 by cDNA transfection also increased PGE2 synthesis, 
but only after treatment with the DNA methyltransferase inhibitor 5-aza-2-
deoxycytidine, indicating reversible silencing of the COX-2 promoter. 
Functionally, the metastatic sublines showed enhanced migration and Matrigel 
invasion in adapted Boyden chamber assays, which further increased by S1P 
stimulation. This response was abrogated by either S1P3 antagonism, COX-2 
inhibition or prostaglandin E2 receptor 2 (EP2) and 4 (EP4) antagonism, but not 
by S1P2 antagonism. Our data demonstrate that in breast cancer cells 
overexpression of S1P3 and its activation by S1P has pro-inflammatory and pro-
metastatic potential by inducing COX-2 expression and PGE2 signaling via EP2 
and EP4. 
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2.1. Introduction 
Breast cancer is the most common and devastating malignancy among 
women behind lung cancer and its metastasis is a major cause of poor prognosis 
[1,2]. The proliferative, migratory and invasive properties of metastatic cancer 
cells undermine the efficacy of available therapies, but more effective 
treatments for advanced breast cancer can only be developed if the molecular 
mechanisms are better understood [3,4]. Recent evidence suggests that 
inflammation is often involved in the malignant progression of solid tumors, 
including breast cancer, and chronic inflammation is a major risk factor for 
breast cancer development, treatment resistance and recurrence [5,6]  
Although the link between inflammation and cancer initiation is well 
established by its ability to generate a pro-proliferative and pro-angiogenic 
environment, its role in metastatic diseases, has been poorly explored. 
Prominent mediators of cancer inflammation include the oncogenic NFκB and 
several cytokines like IL-6, IL-8 and IL-1ȕ, which are activated and 
overexpressed in breast cancer [7,8]. In addition, biologically active lipids like 
eicosanoids are implicated in inflammation and cancer too. The cyclooxygenase 
isoform-2 (COX-2) is frequently overexpressed in solid tumors and activated by 
different cytokines and growth factors to support inflammatory processes and 
migration [9,10]. It generates the metabolite prostaglandin E2 (PGE2), which 
promotes cancer cell growth, stimulates angiogenesis, migration and invasion, 
confers resistance to apoptosis and suppresses immunity [11,12]. Also in breast 
cancer, elevated expression of COX-2 and overproduction of downstream PGE2 
is associated with a metastatic phenotype and poor prognosis [13,14]. The 
biological effect of PGE2 is mediated by binding to EP receptors of which four 
subtypes have been characterized [15,16]. Particularly,  EP2 and EP4 have been 
found to be closely associated with an invasive phenotype in various cancer 
types [17,18]. In breast cancer cells COX-2 induced PGE2 synthesis was shown 
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to increase expression of the pro-invasive CCR7 chemokine via EP2 and EP4 
activation, and in breast cancer tissues overexpression of COX-2 correlates with 
lymph node metastasis [14]. 
 
Recent findings corroborate that malignant progression and 
aggressiveness of breast cancer is also driven by processes involving the 
bioactive sphingolipid metabolite sphingosine 1-phosphate (S1P). S1P has a 
pro-inflammatory potential [19,20] and stimulates cancer-relevant responses 
like cell growth, migration, invasion and angiogenesis [21] . Although S1P 
shows also intracellular distribution, most of its biological effects result from 
binding to cognate G protein-coupled receptors (GPCRs) on the cell surface 
[22,23]. Five subtypes of S1P receptors (S1P1-5), have been identified, each of it 
demonstrates tissue-specific expression and couples to different G proteins [24]. 
As shown in renal mesangial cells and smooth muscle cells, S1P binding to 
S1P2 and S1P3 can induce COX-2 expression and PGE2 synthesis [25,26], and 
from lung cancer cells there is evidence that it activates cPLA2 to produce 
arachidonic acid via S1P3 [27]. In line with these findings, S1P was also 
reported to induce PGE2 synthesis through activation of S1P1 and S1P3 in non-
tumorigenic granulosa cells [28]. Furthermore, increased formation of S1P with 
subsequent activation of S1P1 and the STAT3 pathway links chronic intestinal 
inflammation to colitis-associated carcinogenesis [29], and in breast cancer S1P 
was shown to induce migration and invasion via S1P3-mediated upregulation of 
MMP-9 [30]. S1P is also able to transactivate tyrosine kinase receptors such as 
the EGF receptor and thereby increase EGFR signaling in breast cancer cells 
[31]. On the other hand, in non-malignant cell types anti-inflammatory effects 
of S1P mediated by S1P1, S1P2 and/or S1P3 have been described [32,33], a 
discrepancy which needs to be clarified by further investigations. 
In the present study, we used the breast cancer cell line MDA-MB-231 
and two sublines established from single cell-derived progenies derived from 
lung and bone metastases in nude mice [34,35] to investigate S1P-induced pro-
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inflammatory effects associated with their increased metastatic potential. We 
report that in both metastatic sublines S1P3 is overexpressed and its activation 
by extracellular S1P stimulates COX-2 expression and PGE2 synthesis. PGE2 
binding to EP2 and also EP4 on the metastatic cells increases migration and 
Matrigel invasion in an auto- and paracrine manner thus underpinning their 
aggressive phenotype. 
 
2.2. Materials and methods 
2.2.1.  Chemicals and reagents 
The PGE2-specific ELISA was obtained from Enzo Life Science 
(Lörrach, Germany); human recombinant IL-1ȕ was from PeproTech 
(Hamburg, Germany). Secondary HRP-coupled IgGs, hyperfilm MPR and 
enhanced chemiluminescence reagents were purchased from GE Health Care 
Systems (Glattbrugg, Switzerland). Antibody against COX-2 was from Cell 
Signaling (Schwalbach, Germany); antibody against microsomal prostaglandin 
E synthase-1 (mPGES-1) was from Cayman Chemicals Inc. (Ann Arbor, MI, 
US); antibody against ȕ-actin (clone AC-15) was from Sigma-Aldrich Chemie 
GmbH (Buchs, Switzerland); S1P, VPC23019 and W146 were obtained from 
Avanti Polar Lipids Inc. (Alabaster, AL, USA); JTE013, TY52156, SC51322, 
PF04418948, L-798.106, were from Tocris Bioscience (Bristol, United 
Kingdom); AH23848, digitonin, celecoxib, CYM5541, PGE2, 5‘-aza-β‘-
deoxycitidine (aza-C) and KICqStart®SYBR®Green qPCR ReadyMix™ 
(SYBRgreen) were obtained from Sigma Aldrich Chemie GmbH (Buchs, 
Switzerland); fura-2/AM was from LuBio Science GmbH (Luzern, 
Switzerland); TurboFect™ was from Fermentas Life Science/ThermoFisher 
Scientific (Zug, Switzerland); First Strand DNA Synthesis Kit, was from MBI 
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Fermentas (St-Leon-Roth, Germany); TRIZOL® reagent (5-Prime), Corning® 
Matrigel® Basement Membrane Matrix and growth factor reduced (GFR) 
(Matrigel) were from VWR International AG (Dietikon, Switzerland); all cell 
culture media and supplements were purchased from Invitrogen AG (Basel, 
Switzerland); PCR primers were purchased from Sigma-Aldrich Chemie 
GmbH.  
2.2.2. Cell lines and cell culture conditions  
The human breast cancer cell line MDA-MB-231 and its sublines 4175 
and 1833, which were derived by single-cell cloning from lung and bone 
metastases of nude mice, respectively [34], are from Dr. J. Massagué (Memorial 
Sloan-Kettering Cancer Center, New York, NY, USA). Cells were maintained 
in DMEM medium supplemented with 10% fetal bovine serum, 10 mM HEPES 
pH 7.4, 100 units / ml penicillin and 100 µg/ml streptomycin. All cells were 
grown at 370 C in a humidified atmosphere containing 5 % CO2. 
For S1P2 and S1P3 downregulation, cells were transfected with 
Oligofectamine and 100 nM of a Smartpool siRNA of hS1P2 (Dharmacon, ON-
TARGETplus SMARTpool S1PR2 (L-003952) or hS1P3 (Dharmacon, ON-
TARGETplus SMARTpool S1PR3 (L-005208)) as recommended by the 
manufacturer in 24-well-plates. Control siRNA transfection was performed with 
non-targeting siRNA (On-TARGETplus Control D-001810). 48 h after 
transfection cells were incubated under serum free conditions for 24 h and then 
stimulated with S1P or vehicle for 2 h. 
2.2.3. S1P3 overexpression in MDA-MB-231 cells 
The human S1P3 pcDNA3.1 construct was kindly provided by Dr. D. 
Guerini (Novartis, Basel). Transfection was performed using TurboFect™ 
following the manufacturer’s instructions. Briefly, parental MDA-MB-231 cells 
were subcultured into a 6-well plate for 24 hours to achieve ~70% confluency 
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on the day of transfection. 2 µg of DNA and 6 µl of transfection reagent were 
mixed in 200 µl serum free DMEM and placed drop-wise to each well for 48 
hours. Stable transfectants were obtained under selection conditions in the 
presence of 0,5 mg/ml G418 for 10 -15 days. 
2.2.4. Quantitative real-time PCR  
Total RNA (1 µg) isolated with TRIZOL® reagent (5-Prime) was used for 
reverse transcriptase PCR using the First Strand DNA Synthesis Kit and a 
random hexamer primer for amplification. The real-time PCR reaction was 
performed using SYBRgreen and a BioRad iQ5 Cycler Detection System 
(BioRad Laboratories AG, Glattbrugg, Switzerland). The primer sequences used 
for qPCR are listed in Table 2.1. The fold induction values were obtained 
according to the ΔΔCT method after normalization to the housekeeping gene 
18S RNA. 
 
Table 2.1. Characteristic of primers used for qPCR analysis 
Gene Forward primer (from 5’ to γ’) 
Reverse primer (from 5’ to γ’)  
human S1P1 CCTCTAGCGTTCGTCTGG 
TTTCCCGTGTAGTTGTAATGC 
human S1P2 TCAAGACGGTCACCATCG 
ACAGGCATAGTCCAGAAGG 
human S1P3 CTTACGACGCCAACAAGAG 
CAGGATGGTAGAGCAGTCAG 
human S1P4 TGTTCTGCACTACAACCACTC 
AAGTTCTCCAGCACCACCAG 
human S1P5 TCTTCCTGCTGCTGTTGCTC 
GCGTGTAGATGATGGGGTTCAG 
human COX-1 CTAAAGATTGCCCCACACC 
GTTTCCCATCCTTAAAGAGCC 
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Gene Forward primer (from 5’ to γ’) 
Reverse primer (from 5’ to γ’)  
human COX-2 TGACAGTCCACCAACTTACAATGC 
AATCATCAGGCACAGGAGGAAGG 
human EP1 CACGTGGTGCTTCATCGGCCTGGGTC 
CACCACCATGATACCGACAAG 
human EP2 TCCTGTTCTGAGACTAATGCGTTC 
GTTTACRGGCATCTGACTGTGTAG 
human EP3 GGGCCTGATGGAAGGTGTTT 
TCTATCATGAGAACTGCACCAAGTC 
human EP4 TCTGACCTCGGTGTCCAAAAATCG 
TGGGTACTGCAGCCGCGAGCTA 
 
2.2.5. Cell homogenization and Western blotting  
Cells were washed with phosphate-buffered saline (PBS), scraped into 
ice-cold lysis buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 10% glycerol, 
1% Triton X100, β mM EDTA, β mM EGTA, 40 mM ȕ-glycerophosphate, 50 
mM sodium fluoride, 10 µg ml-1 leupeptin, 10 µg ml-1 aprotinin, 1 µM pepstatin 
A, 1 mM phenylmethyl sulphonyl fluoride) and homogenized by passing 10 
times through a 26-G needle fitted to a 1 ml syringe. Samples were centrifuged 
for 10 min at 1γ’000 x g. The supernatant was taken for protein determination 
and 30 µg protein was separated by SDS-PAGE, transferred to a nitrocellulose 
membrane and subjected to Western blotting as described [36] using the 
antibodies indicated in the figure legends. 
2.2.6. Measurement of [Ca2+]i in cell suspension  
Intracellular Ca2+ was measured essentially as described [37]. Briefly, 
after starvation for 24 hours, cells were washed and suspended in HBSS (118 
mM NaCl, 5 mM KCl, 1 mM CaCl2, 1 mM MgCl2, 5 mM D-glucose and 15 
mM Hepes (pH 7.4), and loaded for 45 min with 1 µM of the Ca2+ indicator dye 
fura-2/AM. Then, the cells were washed twice in HBSS and fura-2 fluorescence 
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was monitored in a spectrofluorometer (Hitachi) using excitation wavelengths 
of 340/380 nm and an emission wavelength of 510 nm. At a stable baseline (250 
sec), S1P was added to a final concentration of 1 µM and the change of 
fluorescence was recorded. At the end of each scan (550 sec), 10 µM of 
digitonin was added to determine the maximum Ca2+ and 10 mM of the 
chelating agent EDTA was added (750 sec) to achieve the minimum 
concentration of Ca2+ in the cell. Data were calculated using the FL WinLab 
program (PerkinElmer AG, Schwerzenbach, Switzerland). 
2.2.7. Measurement of secreted prostaglandin E2  
PGE2 in cell culture supernatants was quantified using a competition 
immunoassay (PGE2-ELISA/EIA kit from Enzo Life Sciences, Lörrach, 
Germany). 100 µl cell supernatants were processed according to the 
manufacturer’s instructions. The absorbance at 405 nm was measured by 
spectrophotometry and the PGE2 concentration was determined with a 
calibration curve using PGE2 as standard.  
2.2.8. Migration and invasion assays  
Cell migration and invasion were measured with an adapted Boyden 
chamber assay. For invasion measurement, transwell filters had been precoated 
with 100 µl of 6 mg/ml Matrigel. Quiescent cells at a density of 2,5 x 105 cells 
in 200 µl starvation medium (0.1mg/ml-1 fatty acid-free bovine serum albumin) 
were seeded into the transwell filters (6,5 µm diameter, 8 µm pore size). 750 µl 
of serum free or complete growth medium (for migration and invasion assays, 
respectively) was placed in the lower compartment and cells were incubated at 
37°C for the indicated time periods to allow migration/invasion. Thereafter, 
transwell filters were removed and cells which had migrated/invaded through 
the filter into the lower chamber were counted in four different random fields 
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for one sample using a Nikon TMS-F microscope (Nikon AG, Egg/ZH, 
Switzerland).  
2.2.9. Statistical analysis  
Statistical analysis of data was performed using one-way ANOVA 
following Dunnett post-hoc test for multiple comparisons or unpaired t-test 
when only two groups were compared. 
  
2.3. Results 
2.3.1. S1P3 is upregulated in metastatic breast cancer cells and its 
activation by S1P induces intracellular calcium mobilization 
The role of S1P and its cognate cell surface receptors in breast cancer 
metastases is still unclear. Here, we used the breast cancer cell line MDA-MB-
231 and the two sublines 4175 and 1833 derived from lung and bone 
metastases, respectively, in nude mice [34], to determine the S1P receptor 
subtype associated with the metastatic phenotype. First, parental and metastatic 
MDA-MB-231 cells were characterised for S1P receptor expression using 
quantitative PCR. As shown in Fig. 1, the parental MDA-MB-231 cells showed 
the highest mRNA levels for S1P3 and S1P5 among the different receptor 
subtypes, low expression of S1P1 and S1P2, whereas S1P4 was undetectable. For 
comparison, in both metastatic sublines expression of S1P3 was strongly 
enhanced and reached particularly high levels in 1833 cells. The S1P1 was 
downregulated in both metastatic sublines whereas the other S1P receptors 
showed a similar expression pattern as in parental MDA-MB-231 cells (Fig. 1). 
To verify that overexpression of S1P3 in the metastatic MDA-MB-231 
sublines is coupled to increased S1P3 receptor signalling, we investigated 
whether Ca2+ mobilization as an early read-out of receptor activation [23,37] 
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Fig. 1. mRNA expression profile of S1P1-5 receptors in parental and metastatic MDA-MB-231 
cells. Confluent cells were incubated in serum-free medium for 24 h. Thereafter, RNA was extracted 
and taken for quantitative PCR analysis of S1P1-5 using the primers indicated in the Materials and 
Methods section. 18S RNA was used for normalization. Data are expressed as a % to the S1P1 
expression in parental MDA-MB-231 cells and are the mean ± SD (n=4). ***p< 0.0001 compared to 
S1P1 expression in parental MDA-MB-231 cells. 
 
increased in the presence of extracellular S1P. To this end, cells were loaded 
with the Ca2+ indicator fura-2/AM and stimulated with S1P. As shown in Fig. 
2A, the parental MDA-MB-231 cells responded to S1P with only a marginal 
increase in intracellular Ca2+ ([Ca2+]i). In contrast, in both metastatic sublines, 
which had higher basal ([Ca2+]i levels, S1P induced a 6- to 8-fold increase of  
[Ca2+]i compared to the parental cells (Fig. 2A, B). In all cell lines, pre-
treatment with the S1P1/3 antagonist VPC23019 effectively blocked S1P-induced 
Ca2+ mobilization. The S1P1 antagonist W146 had no effect on any of the cell 
lines and the S1P2-selective antagonist JTE013 suppressed [Ca2+]i increase only 
in the parental cells (Fig. S1A, S1B). A selective S1P5 antagonist is not yet 
available and therefore, this receptor subtype could not be explicitly excluded. 
The increase in baseline Ca2+ mobilization measured upon pre-treatment of 4175 
cells with all three antagonists (Fig. S1A) might be due to a decreased inhibitory 
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activity of the Gi-coupled receptors. The pattern of responsiveness to the various 
antagonists together with the receptor subtype expression profiles shown in Fig. 
1 confirms that S1P3 overexpressed on the metastatic MDA-MB-231 cells is 
fully functional and represents the major receptor involved in S1P-induced Ca2+ 
mobilization. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2. Effect of exogenous S1P on intracellular calcium [Ca2+]i  mobilization in parental and 
metastatic MDA-MB-231 cells. Cells were loaded with fura-2/AM prior to stimulation with 1 µM 
S1P and [Ca2+]i was measured as described in the Materials and Methods section. (A) Representative 
curves from parental MDA-MB-231 cells and the metastatic sublines. (B) Maximum S1P-induced 
peak level of Ca2+ expressed as % of the parental MDA-MB-231 cells. Data are the mean ± SD (n=3). 
***p< 0.001 compared to parental MDA-MB-231 cells. (C) Cells were pretreated for 10 min with the 
S1P1/3 antagonist VPC23019 (V, 10 µM), the S1P1 antagonist W146 (W, 10 µM) or the S1P2 
antagonist JTE013 (J, 10 µM) prior to stimulation with 1 µM S1P. [Ca2+]i was measured and peak 
levels determined. Data are the mean ± SD (n=3). **p<0.01, ***p<0.001, compared to parental MDA-
MB-231 cells; #p<0.05, ##p<0.01, ###p<0.001 compared to the corresponding S1P-treated cells. 
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2.3.2. COX-2 and mPGES-1 are upregulated in metastatic breast cancer  
There is evidence that COX-2 and its product PGE2 are implicated in 
breast cancer metastasis [13,14]. Here, we investigated whether COX-2 and 
PGE2 are also upregulated in the two metastatic MDA-MB-231 sublines. As 
shown in Fig. 3 A, the untreated metastatic sublines already produce higher 
basal amounts of PGE2 compared to the parental MDA-MB-231 cells. 
Treatment of cells with the inflammatory cytokine interleukin (IL)-1ȕ together 
with forskolin (Fk), a regimen known to synergistically upregulate PGE2 [38], 
only very slightly increased PGE2 in the parental cells but triggered a strong 
increase in both metastatic sublines (Fig. 3A). As shown in Fig. 3B and Fig. S2, 
basal COX-2 and COX-1 mRNA expression was higher in the metastatic cells 
compared to the parental cells. Most importantly, however, similar to PGE2 
synthesis IL-1ȕ/Fk strongly increased COX-2 mRNA expression (Fig. 3B) and 
protein expression (Fig. 3D) in the metastatic cells, whereas COX-1 expression 
even slightly decreased (Fig. S2). This strongly suggests that the high level of 
PGE2 was produced by COX-2. Again, in the parental MDA-MB-231 cells the 
effect of IL-1ȕ/Fk on COX-2 and COX-1 expression was marginal (Fig. 3B, 
Fig. S2). 
Another downstream enzyme which is involved in PGE2 synthesis and 
inducible by inflammatory mediators is the microsomal prostaglandin E 
synthase-1 (mPGES-1). We found that in the metastatic MDA-MB-231 cells 
mPGES-1 is also upregulated on the mRNA and protein level, and is strongly 
inducible by IL-1ȕ/Fk (Fig. γC, D). Again, in the parental MDA-MB-231 cells 
the effect of IL-1ȕ/Fk on mPGES-1 expression was low (Fig. 3C, D). Since IL-
1ȕ/Fk is known as a strong inducer of COX-2 and mPGES-1 in many cell types, 
we wondered whether the here observed weak effect in the parental MDA-MB-
231 cells was due to suppression by promoter silencing, as such epigenetic 
regulation was reported also for other genes during metastatic selection in this 
cell line [39]. In fact, treatment of the parental cells with the DNA              
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Fig. 3. PGE2 synthesis and mRNA expression of COX and mPGES-1 in parental and metastatic 
MDA-MB-231 cells.  Cells were incubated for 24 h in serum-free medium prior to stimulation for 24 
h with either vehicle control (-) or a combination of IL-1ȕ (1 nM) plus forskolin (Fk, 5 µM). (A) 
Supernatants were taken for PGE2 quantification by ELISA as described in the Materials and Methods 
section. Data are expressed as pg of PGE2 per ml supernatant and are the mean ± S.D. (n=3). (B and 
C) Cells were taken for RNA extraction and quantitative PCR analysis of COX-2 (B) and mPGES1 
(C). Data are the mean ± S.D. (n=3). **p<0.01, ***p<0.001 compared to unstimulated parental 
MDA-MB-231 cells; ###p<0.001 compared to unstimulated 4175 cells; §§§p < 0.001, compared to 
unstimulated 1833 cells. (D) Cells were taken for protein extraction, separation by SDS-PAGE (8 % 
gels for COX-β and ȕ-actin, 15 % gels for mPGES-1) and Western blotting using antibodies against 
COX-2 (upper panel), mPGES-1 (middle panel) and ȕ-actin (lower panel). Blots are representative of 
three independent experiments showing similar results. 
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methyltransferase inhibitor 5-aza-β’-deoxycitidine (aza-C) increased COX-2 
mRNA and protein expression (Fig. S3A, B), suggesting that the COX-2 
promoter is silenced in these cells by methylation. 
2.3.3. S1P induces COX-2 expression and PGE2 synthesis in metastatic 
breast cancer cells via S1P3 
To investigate the possibility that the high COX-2 expression and PGE2 
synthesis in the metastatic MDA-MB-231 cells is induced by S1P via 
overexpressed S1P3, we treated parental and metastatic cells with exogenous 
S1P and measured COX-2 mRNA expression and PGE2 synthesis at different 
time points. Fig. 4A shows that in parental MDA-MB-231 cells S1P induced 
only a marginal time-dependent increase of COX-2 mRNA expression, 
consistent with the finding that the COX-2 gene is silenced in these cells. On 
the other hand, in the two metastatic sublines S1P induced a strong time-
dependent increase in COX-2 mRNA expression with peak values reached after 
2 to 4 hours, which then returned to low basal levels. COX-2 protein expression 
behaved similarly, peaked at 2-4 hours and thereafter declined to control levels 
over the next hours (data not shown). As expected, quantification of PGE2 in the 
cell culture supernatants revealed that S1P strongly accelerated PGE2 synthesis 
in the metastatic cells compared to the parental cells (Fig. 4B). Notably, the 
secreted PGE2 levels remained constantly high over 24 hours of S1P 
stimulation. The basal PGE2 secretion over time was low but steadily increased 
over 24 h (Fig. S4) 
To further investigate the mechanism underlying S1P-induced PGE2 
overproduction, the COX-2-selective inhibitor celecoxib was used. As shown in 
Fig. 5A, celecoxib dose-dependently blocked S1P-stimulated PGE2 synthesis in 
the metastatic cells, confirming that particularly the COX-2 enzyme is 
responsible for PGE2 overproduction induced by S1P. Furthermore, the use of 
various S1PR antagonists demonstrated that S1P-induced PGE2 synthesis is  
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Fig. 4. Time-dependent effect of S1P on COX-2 mRNA expression and PGE2 formation in 
parental and metastatic MDA-MB-231 cells. Cells were stimulated for 1-24 h with S1P (1 µM). (A) 
Cells were taken for RNA extraction and subjected to quantitative PCR analysis of COX-2. 18S RNA 
expression levels were used for normalization. Data are the mean (n=2). (B) Cell supernatants were 
collected for PGE2 determination by ELISA. Data are expressed as pg of PGE2 per ml of supernatant 
and are the mean ± S.D. (n=3). **p<0.01, ***p<0.001 compared to the corresponding unstimulated 
control cells. 
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effectively abolished by the S1P1/3 antagonist VPC23019 and the S1P2 
antagonist JTE013, but not by the S1P1-selective antagonist W146, suggesting 
that S1P2, despite its low expression, and S1P3 are involved (Fig. 5B). The 
selective S1P3 agonist CYM5541 and the selective S1P2 agonist CYM5520 also 
enhanced PGE2 synthesis (Fig. 5C), thus strongly suggesting a critical role of 
both receptors. In a different approach, we downregulated S1P2 and S1P3 in 
4175 cells by transfection with specific siRNAs. This downregulated approx. 
80% of S1P2 and 85-90% of S1P3 in lung and bone metastatic cells (Fig. S5) 
and both treatments also inhibited S1P-stimulated PGE2 synthesis to a similar 
extent (Fig. 5D), thus confirming that both receptors are involved in PGE2 
synthesis.  
In addition, to confirm that S1P3 activates PGE2 synthesis, we stably 
overexpressed S1P3 in parental MDA-MB-231 cells (Fig. 6A). Consistent with 
the fact that the COX-2 promoter is silenced in these cells, overexpression of 
S1P3 alone and upon stimulation with S1P did not increase PGE2 production 
(Fig. 6B). However, when the S1P3-overexpressing cells were stimulated with 
S1P in the presence of the demethylating agent aza-C, PGE2 production was 
strongly increased compared to untransfected control cells (Fig. 6B). 
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Fig. 5. Effect of celecoxib and S1PR modulators on S1P-induced PGE2 synthesis in parental and 
metastatic MDA-MB-231 cells. (A) Cells were stimulated for 24 h with either vehicle control (Co) 
or 1 µM S1P in the absence (-) or presence of the indicated concentrations of celecoxib. (B) Cells 
were stimulated for 24 h with either vehicle (Co) or S1P (1 µM) in the absence (-) or presence of the 
S1P1+3 antagonist VPC23019 (V, 10 µM), the S1P2 antagonist JTE013 (J, 10 µM), the S1P1 antagonist 
W146 (W, 10 µM) or with the S1P3 agonist CYM5541 (C, 10 µM). All antagonists were added 30 
min prior to S1P stimulation. (C) 4175 cells were stimulated for 2 h with the S1P3 agonist CYM5541 
2 agonist CYM5520 (2 and 10 µM). (D and E) 4175 cells were transfected 
with either control siRNA (D and E, NT-siRNA), siRNA against S1P2 (D, siS1P2) or siRNA against 
S1P3 (E, siS1P3) as described in the Methods section. Thereafter, cells were stimulated for 2 h and 6 h 
with  Supernatants were taken for PGE2 quantification by ELISA. Data are the mean ± 
S.D. (n=3). **p<0.01, ***p<0.001 compared to the corresponding unstimulated vehicle-treated cells; 
#p<0.05, ##p<0.01, ###p<0.001 compared to the corresponding S1P-stimulated cells. 
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Fig. 6. Effect of S1P3 overexpression in parental MDA-MB-231 cells on PGE2 synthesis. (A) 
Parental MDA-MB-231 cells were either treated with vehicle control or transfected with a pcDNA3.1 
vector containing the human S1P3 cDNA (OE) for 48 h. Thereafter, cells were taken for RNA 
extraction and quantitative PCR analysis of S1P3. Data are the mean ± S.D. (n=3). (B) Untransfected 
MDA-MB-231 cells and S1P3 overexpressing cells (OE) were treated with vehicle control (Co) or 5 
µM aza-C (+) for 3 days (fresh aza-C was added every 24 h). Then, cells were starved for 4 h and 
subsequently stimulated for 2 h with S1P (1 µM). Supernatants were taken for PGE2 quantification by 
ELISA. Data are the mean ± S.D. (n=3). *p<0.05, ***p<0.001 compared to the corresponding 
vehicle-treated untransfected control cells; ###p<0.001 compared to the corresponding aza-C-treated 
cells.  
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2.3.4. S1P/S1P3 increases migration of metastatic breast cancer cells in 
a COX-2 and PGE2-dependent manner 
PGE2 is a major pro-migratory prostanoid and implicated in metastasis 
[12]. Here, we investigated whether the high expression level of S1P3 
contributes to the metastatic phenotype of the MDA-MB-231 sublines by 
mediating S1P-induced COX-2 and PGE2 synthesis. To this end, the migratory 
potential of cells was determined using an adapted Boyden chamber assay. As 
expected, the metastatic sublines migrated significantly faster than the parental 
cells and also strongly responded to S1P (Fig. 7A). Similarly, PGE2 added to the 
upper chamber further strongly enhanced the migration of the metastatic 
variants whereas the parental cells were only marginally responsive (Fig. 7A). 
As shown in Fig. 7B, the S1P1/3 antagonist VPC23019 and the recently 
developed S1P3-selective antagonist TY52156 [40] both effectively offset S1P-
induced migration. In contrast, the S1P2 antagonist JTE-013 failed to reduce 
S1P-stimulated migration (Fig. 7C).  
Next, we examined, whether COX-2 is directly involved in the pro-
migratory effect of S1P. To this end, we treated cells with the selective COX-2 
inhibitor celecoxib to abrogate PGE2 synthesis. Fig. 7D shows that celecoxib 
indeed inhibited S1P-induced cell migration in both metastatic sublines. This 
suggests that the pro-migratory effect of S1P/S1P3 signaling is mediated by 
increased PGE2 synthesis and secretion, followed by activation of cognate EP 
receptors on the metastatic cells in an auto- and paracrine manner. 
In a control experiment presented in Fig. 7E, we examined the pro-
migratory effect of S1P on parental cells MDA-MB-231 cells overexpressing 
S1P3 by transfection. In untransfected control cells S1P alone induced a 
measurable but marginal increase of migration as expected from the relative 
lack of COX-2 and PGE2 expression in these cells. Surprisingly, however, we 
found that also aza-C had only a very marginal stimulatory effect and even in  
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Fig. 8. Effect of S1P and PGE2 on the migration of parental S1P3-overexpressing MDA-MB-231 
cells and of metastatic MDA-MB-231 cells. (A) 2 x 105 parental and metastatic cells were seeded 
onto transwell filters and treated for 20 h with either vehicle (Co), S1P (1 µM) or PGE2 (1 µM) under 
serum-free conditions. (B) 2 x 105 parental and metastatic cells were seeded onto transwell filters and 
treated for 20 h with either vehicle (Co) or S1P (1 µM) in the absence (-) or presence of the S1P3 
antagonists VPC23019 (V, 10 µM) or TY52156 (TY, 1 µM). (C) 4175 cells were seeded onto 
transwell filters and treated for 20 h with either vehicle (Co) or S1P (1 µM) in the absence (-) or 
presence of the S1P2 antagonist JTE013 (1 μM and 10 μM). (D) 2 x 105 parental and metastatic cells 
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were seeded onto transwell filters and treated for 20 h with either vehicle (Co) or S1P (1 µM) in the 
absence (-) or presence of celecoxib (CLX, 5 µM). (E) 2 x 105 parental and S1P3-overexpressing cells 
(OE) were seeded onto transwell filters and treated for 20 h with either vehicle (Co) or S1P (1 µM) in 
the absence or presence of aza-C. Migrated cells were determined as described in the Materials and 
Methods section. Data are expressed as number of cells migrated to the lower chamber cells and are 
the mean ± SD (n=3). In A: **p<0.01, ***p<0.001 compared to vehicle-treated parental MDA-MB-
231 cells; ###p<0.001 compared to vehicle-treated 4175 cells; §p<0.05 compared to vehicle-treated 
1833 cells. In B, C, D: **p<0.01, ***p<0.001 compared to the corresponding vehicle-treated cells; 
#p<0.05, ##p<0.01, ###p<0.001 compared to the corresponding S1P-stimulated cells.  
 
cells overexpressing S1P3, which overproduce PGE2 in the presence of S1P and 
aza-C (Fig. 7E), the migratory response did not markedly increase compared to 
the untransfected cells. This indicates that in parental MDA-MB-231 cells 
additional defects are involved which negatively affect migration. 
2.3.5. PGE2 stimulates migration and invasion of metastatic breast 
cancer cells by EP2 and EP4 activation 
To investigate the role of the EP subtypes in PGE2-stimulated cell 
migration, we measured mRNA expression of the four known receptor EP1-4. 
EP2 was highly upregulated in both metastatic sublines with the highest level 
measured in 1833 cells (Fig. 8A). Expression of the other receptor subtypes was 
much lower and similar in the three cell lines, except for EP4, which was 
slightly higher in 1833 cells (Fig. 8A). 
To investigate whether the highly expressed EP2 is involved in the pro-
migratory action of PGE2 in metastatic 4175 cells, we used antagonists selective 
for all four receptor subtypes. Fig. 8B shows that antagonism of EP2 (by 
PF04418948) and EP4 (by AH23848) attenuated S1P-induced migration. In 
contrast, an EP1 antagonist (SC51322) and an EP3 antagonist (L-798.106) were 
inefficient. This indeed suggests a pro-migratory stimulation loop initiated by 
S1P binding to S1P3, which results in PGE2 overproduction and secretion  
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Fig. 8. mRNA expression of EP1-4 in parental and metastatic MDA-MB-231 cells and effect of 
EP antagonists on S1P-induced migration. (A) Cells were cultured for 24 h in serum-free medium 
before RNA was extracted for PCR analysis of the PGE2 receptor subtypes EP1-4. 18S RNA was used 
for normalisation. Data are the mean ± SD (n=6), ***p<0.0001. (B) 2 x 105 4175 cells were seeded  
on transwell filters and treated for 20 h with vehicle control (Co) or S1P (1 µM) in the absence (-) or 
presence of the EP1 antagonist SC51322 (SC, 5 µM), the EP2 antagonist PF04418948 (PF, 5 µM), the 
EP3 antagonist L-798.106 (L, 5 µM) or the EP4 antagonist AH23848 (A, 5 µM). Migrated cells were 
counted as described in the Materials and Methods section.  Data are expressed as number of cells 
migrated to the lower chamber cells and are the mean ± SD (n=3). **p<0.01 compared to the 
corresponding vehicle-treated control cells; ##p < 0.01 compared to the corresponding S1P-stimulated 
cells.  
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followed by activation of EP2 and EP4. The low level of EP2 expression on 
parental MDA-MB-231 cells might explain why S1P3 overexpression and aza-C 
could only partially increase the migratory potential (Fig. 7D) 
Finally, as another hallmark of metastasis we examined the invasive 
potential of the MDA-MB-231 cell lines resulting from EP2 and EP4 signalling. 
To this end, parental and metastatic cells were allowed to migrate through a 
membrane covered with Matrigel in a transwell system. Similar to migration, 
the metastatic cells showed stronger invasion compared to the parental cells and 
it further increased significantly upon stimulation with S1P or PGE2 (Fig. 9A). 
Moreover, as shown in Fig. 9B for the metastatic 4175 subline, the selective 
S1P3 antagonist TY52156, the COX-2 inhibitor celecoxib and the EP2 and EP4 
antagonists (PF04418948 and AH23848, respectively) all significantly offset 
the stimulatory effect of S1P on invasion. Together with the data from the 
migration assay, this suggests a crucial role of EP2 and EP4 in the pro-metastatic 
activity of PGE2 in breast cancer. 
 
2.4. Discussion 
Inflammatory breast cancer is a metastatic disease characterized by an 
aggressive and invasive phenotype [5,6]. To investigate the role of S1P and its 
cognate receptors in inflammation and metastasis, we used a breast cancer 
metastases model based on the MDA-MB-231 cell line and the two sublines 
4175 and 1833 established from single cell-derived progenies with enhanced 
metastatic ability to lung and bone, respectively, by in vivo selection [34,35]. 
All three cell lines express a common poor-prognosis gene expression signature, 
demonstrating that the metastatic clones already pre-exist in the parental cell 
population, which is derived from a pleural effusion, but in addition show a 
gene expression profile characteristic for their organ-specific localization  
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Fig. 9. Effect of S1P and PGE2 stimulation on invasion of parental and metastatic MDA-MB-231 
cells. (A) 2 x 105 cells were seeded onto Matrigel-coated transwell filters and treated for 48 h with 
either vehicle control (Co), S1P (1 µM) or PGE2 (1 µM). (B) 2 x 105 4175 cells were seeded onto 
Matrigel-coated transwell filters and treated for 48 h with vehicle control (Co) or S1P (1 µM) in the 
absence (-) or presence of celecoxib (CLX, 5 µM), the S1P1/3 antagonists VPC23019 (V, 10 µM) and 
TY52156 (TY, 1 µM), the EP1 antagonist SC51322 (SC, 5 µM), the EP2 antagonist PF04418948 (PF, 
5 µM), the EP3 antagonist L-798.106 (L, 5 µM) or the EP4 antagonist AH23848 (A, 5 µM). Invaded 
cells were determined as described in the Materials and Methods section. Data are expressed as 
number of cells migrated through the Matrigel-coated membrane into the lower chamber and are the 
mean ± SD (n=3). In A: **p<0.01, ***p<0.001 compared to vehicle-treated parental MDA-MB-231 
cells; ###p<0.001 compared to vehicle-treated 4175 cells; §p<0.05 compared to vehicle-treated 1833 
cells. In B: **p<0.01 compared to vehicle-treated 4175 cells; #p<0.05, ##p<0.01, compared to S1P-
treated 4175 cells. 
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[34,35]. The selection of such pre-existing highly metastatic clones from a 
parental cell population offers the possibility to compare cells with a very 
similar genetic background and specifically identify differences associated with 
increased metastasis. Here, we investigated such differences with focus on S1P 
receptor signaling as this pathway was shown to be implicated in inflammatory 
processes and to support pro-metastatic features like migration and invasion 
[20]. We did not further explore differences related to the site of metastasis of 
the MDA-MB-231 sublines, i.e. lung and bone. Interestingly, we found that the 
three cell lines revealed distinct profiles of S1P3 receptor expression, which was 
much higher in both metastatic sublines compared to the parental cell 
population. We are unable to present data on the protein level as several 
commercially available S1P3 antibodies revealed irrelevant unspecific bands by 
Western blotting (data not shown). This has recently been reported as a 
potential serious drawback if antibodies against GPCR proteins are used and 
may question published data on these targets [41]. S1P3 overexpression has not 
yet been described by transcriptomic analyses of these cell lines so far, and little 
is known about its implication in breast cancer development and metastatic 
progression. 
S1P3 couples to Gi, Gq and G12/13 [23]. Upon S1P binding, one of the fast 
intracellular responses mediated by S1P3/Gq is induction of PLC/IP3 signaling 
and Ca2+ mobilization [30]. S1P3 overexpressed on the metastatic sublines was 
fully functional and increased [Ca2+]i upon stimulation with extracellular S1P. 
Accordingly, the basal level of [Ca2+]i in these cells is higher compared to the 
parental cell line, and stimulation with S1P further induced [Ca2+]i in the 
metastatic, but not in the parental cell lines. As expected, this response to S1P 
was mitigated particularly by the S1P1,3 antagonist VPC23019 [42] (Fig. S1), 
corroborating previous findings that S1P3 and S1P2 can both increase Ca2+ 
mobilization [43]. However, we are aware that the antagonists do not fully 
discriminate between all receptor subtypes and may even dose-dependently 
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cross-react as partial agonists [42,44], these data thus only indicate a trend and 
must be considered in the context of the receptor expression profiles. Similarly, 
without S1P stimulation we also measured a higher baseline of intracellular 
Ca2+ in the presence of VPC23019 in the metastatic sublines, however, we 
hypothesize that this was due to suppression of the inhibitory activity of Gi-
coupled S1P3.  
In the metastatic MDA-MB-231 sublines activation of S1P3 also 
increased COX-2, but not COX-1 expression, and consequently synthesis of the 
biologically active prostanoid PGE2, which could be measured in the culture 
supernatants. Enhanced COX-2 expression is frequently found in invasive 
breast cancer [13] and was identified as a hallmark and poor prognosis gene 
expression signature of metastatic MDA-MB-231 cells [34,35]. In line with this 
finding we also measured constitutively high levels of COX-2 in the two 
metastatic sublines compared to the parental cells, and expression could be 
further increased by treatment with IL-1ȕ/Fk, a potent inducer of the enzyme 
[45]. In contrast, the parental cells expressed only very low levels of COX-2 
and also did not respond to IL-1ȕ/Fk. Interestingly, further investigations using 
the demethylating agent aza-C [46] unveiled COX-2 promoter silencing in the 
parental cell population, which in the two sublines was apparently suspended 
during metastatic selection. 
PGE2 is implicated in various pathological processes such as 
inflammation and cancer, and its role in carcinogenesis and tumor growth is 
well established [12]. On the other hand, the PGE2 analog 16,16-dimethyl-PGE2 
was shown to inhibit intestinal tumor formation and growth [47]. Here, we 
found that in both metastatic MDA-MB231 sublines the high levels of COX-2 
correlated with PGE2 synthesis, whereas PGE2 was hardly detectable in the 
parental cell line (Fig. 3A). mPGES-1 is another inflammation-relevant enzyme 
which is implicated in the synthesis of inducible PGE2 and its expression is also 
associated with tumor growth and metastasis [48]. In fact, compared to the 
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parental MDA-MB-231 cell line we measured also higher levels of IL-1ȕ/Fk-
inducible mPGES-1 in the metastatic sublines, suggesting that it also 
contributes to the higher basal level of PGE2 synthesis in these cells. 
The pro-inflammatory action of S1P may be due to its ability to stimulate 
COX-2 expression and subsequent synthesis of PGE2 [25,26,28]. Indeed, we 
found that S1P induced COX-2 expression and PGE2 synthesis particularly in 
the metastatic MDA-MB-231 cells, and the use of antagonists selectively 
binding to the different S1P receptor subtypes unveiled that this effect was due 
to activation of the overexpressed S1P3. Further evidence for the role of S1P3 in 
PGE2 synthesis was provided by S1P3 downregulation using siRNA and 
pharmacologically using the S1P3 agonist CYM5541 [49], which showed a 
similar effect as S1P on the metastatic cells. These findings were corroborated 
by our data from parental MDA-MB-231 cells overexpressing S1P3 upon 
transfection. However, as discussed above for COX-2 expression, despite very 
high S1P3 levels, treatment with S1P alone was ineffective in the parental 
MDA-MB-231 cells and pretreatment with the DNA demethylating agent aza-C 
was required to stimulate PGE2 synthesis. This suggests silencing of the COX-2 
promoter as an epigenetic mechanism which was reported also for other genes 
involved in breast cancer metastasis [39]. These findings demonstrate that S1P 
by activation of S1P3 has potential to induce the COX-2/PGE2 pathway, thereby 
contributing to the pro-inflammatory environment in metastatic breast cancer. 
The pro-migratory potential of S1P and PGE2 has been described in 
various cell types  [18,20,50,51]. In addition, in cancer, PGE2 also stimulates 
the angiogenic switch and was shown to promote lymphatic invasion of breast 
cancer cells [14]. As expected from the several rounds of in vivo selection in 
nude mice [34], compared to the parental MDA-MB-231 cells the metastatic 
sublines, particularly 4175, exhibited a higher migratory potential and tissue 
invasion, which further increased in the presence of exogenous S1P or after the 
treatment with recombinant PGE2. Using various S1P receptor subtype-selective 
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antagonists we could confirm that this effect was mediated by S1P3, which is 
overexpressed exclusively in the two metastatic MDA-MB-231 sublines. This 
finding is corroborated by recent data from lung cancer cells where knockdown 
of S1P3 mitigated S1P-induced migration and invasion [52] and from a 
melanoma metastasis model where S1P3 stimulated motility and invasiveness 
triggered by stroma-derived S1P [53]. In breast cancer patients high 
cytoplasmic S1P3 expression in tumors was shown to correlate with shorter 
survival and nuclear S1P3 expression to correlate with tumor size [54]. In vitro 
data from other cancer types also suggest different scenarios for this pro-
metastatic S1P3-dependent effect, including Gi-mediated activation of the Rho 
family GTPase Rac [51] or interaction of Gq with MMP-9 [30]. Using the COX-
2 inhibitor celecoxib we clearly demonstrate that the COX-2/PGE2 pathway is 
implicated in S1P/S1P3-induced migration and invasion of the here used in vivo 
selected metastatic breast cancer cells.  
Similar to S1P3 we found that S1P2 was also involved in PGE2 synthesis 
and its antagonism disrupted S1P-induced PGE2 synthesis. A role of S1P2 in 
cyclooxygenase 2 expression was previously also reported by others. Thus, Li et 
al. [55–57] showed that in a Wilms tumor-derived cell line, S1P-stimulated 
COX-2 expression occurs in a S1P2-dependent manner and that S1P2 is greatly 
increased in Wilms tumor tissue. Also, in renal mesangial cells, COX-2 
induction by S1P was mediated by S1P2 [25,26], whereas Kim et al. [55–57] 
reported for amnion-derived WISH cells an exclusive regulation of COX-2 by 
S1P1 and 3, but not by S1P2. Interestingly, although S1P2 stimulation also 
increases PGE2 synthesis in metastatic MDA-MB-231 cells, in contrast to S1P3 
it does not increase migration. This suggests that S1P2 provides additional 
cellular signals which counteract the pro-migratory potential of S1P3 and PGE2. 
One such mechanism could be activation of the Rho-kinase 1 which was 
reported to be regulated by S1P2 (reviewed in [55–57]). The outcome of 
increased migration of the metastatic MDA-MB231 sublines compared to the 
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parental MDA-MB231 cells may thus be the result of S1P3 overexpression 
which outweighs the anti-migratory function of S1P2. Moreover, in the lung 
metastatic cell line 4175 we could not confirm that S1P2 downregulates the 
breast carcinoma metastasis suppressor 1 (Brms1) (data not shown), a response 
which in other cancer cell types was reported to promote lung metastasis [58]. 
PGE2 binds to four EP subtypes, i.e., EP1-4 [15,16]. Particularly, EP2 and 
EP4 are often associated with an aggressive and invasive cancer phenotype 
[17,18] and EP2 was shown to mediate the pro-angiogenic effect of PGE2 in a 
breast cancer metastases model [59]. Both receptors signal through Gs and 
increase cAMP, which may explain how stimulation of COX-2/PGE2 increases 
expression of the CCR7 chemokine. Furthermore, in breast cancer tissues 
overexpression of COX-2 correlates with lymph node metastasis [14]. We 
found that the four receptor subtypes were expressed in the parental and the 
metastatic MDA-MB-231 cell lines though at different levels. EP2 showed the 
highest expression and was upregulated in the two metastatic sublines, whereas 
EP3 was hardly detectable (Fig. 9A). Using receptor subtype-selective 
antagonists we identified EP2 to be mainly responsible for the stimulatory effect 
of S1P on migration and invasion of the metastatic cells, whereas EP4 revealed 
only a moderate effect. 
Altogether, our data demonstrate for the first time that S1P3 
overexpression is a potential marker of metastatic breast cancer and that its 
activation by S1P stimulates the pro-inflammatory
 
COX-2/PGE2 pathway, 
which uses the EP2 and EP4 receptor to promote cell migration and invasion in 
an auto- and paracrine manner. The finding that COX-2 expression is low in 
parental MDA-MB-231 cells line but high and inducible in the metastatic 
sublines, suggests an epigenetic silencing mechanism which becomes 
suspended during in vivo metastatic selection. We conclude that targeting S1P3 
holds promise for the treatment of inflammation-associated metastatic breast 
cancer. 
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Fig. S1. Effect of different S1PRs antagonists on S1P-induced [Ca2+]i mobilization in parental 
and metastatic MDA-MB-231 cells. Cells were loaded with fura-2/AM prior to stimulation with 1 
µM S1P in the absence (Co) or presence of the S1P1/3 antagonist VPC23019 (V, 10 µM), the S1P1 
antagonist W146 (W, 10 µM) or the S1P2 antagonist JTE013 (J, 10 µM). All antagonists were added 
10 min prior to S1P stimulation. [Ca2+]i was measured using a spectrofluorometer as described in the 
Materials and Methods section. A) Representative curves from parental MDA-MB-231 cells and the 
metastatic sublines. Results were calculated using the FL WinLab program.  
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Fig. S2. Expression of COX-1 mRNA in parental and metastatic MDA-MB-231. Cells were incubated for 24 
h in serum-free medium prior to stimulation for 24 h with either vehicle control (-) or a combination of IL-1ȕ 
(1nM) plus forskolin (Fk, 5 µM). Cells were taken for RNA extraction and PCR analysis of COX-1. Data are the 
mean ± S.D. (n=3). *p<0.05, **p<0.01 compared to unstimulated parental MDA-MB-231 cells 
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Fig. S3: Effect of the DNA methyltransferase inhibitor aza-C on COX-2 expression in parental 
MDA-MB-231 cells. Cells were treated for 72 h with either vehicle control (Co) or aza-C (5 µM), 
which was freshly added every 24 h. Thereafter, cells were collected for RNA extraction and 
quantitative PCR analysis of COX-2 (A) or were taken for protein extraction, separation by SDS-
PAGE (8 %) and Western blotting (B) using antibodies against COX-β (B, upper panel) and ȕ-actin 
(B, lower panel), both at dilutions of 1:1000. Data in A are the mean ± S.D. (n=3). ***p<0.001 
compared to vehicle-treated control cells. In B, a representative blot from three independent 
experiments are shown with samples loaded in triplicates. 
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Fig. S4: Basal PGE2 secretion in the absence of S1P in parental and metastatic MDA-MB-231 
cells. Cells were incubated for 1-24 h in DMEM and thereafter, cell supernatants were collected for 
PGE2 determination by ELISA. Data are expressed as pg of PGE2 per ml of supernatant and are the 
mean ± S.D. (n=3). **p<0.01compared to the parental cell values at 24 h. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. S5: Downregulation efficiency of siRNA against S1P2 and S1P3 in lung and bone metastatic 
cell lines. Cells were transfected as described in the Methods Section and thereafter taken for RNA 
extraction and qPCR analysis of S1P2 (left panel) or S1P3 (right panel). Data are means +/- S.D. 
(n=3). 
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My particular contribution to this project was in studying the role of S1P3 
in proliferation of mMC by using cells isolated from Wt and S1P3ko mice. For 
this, I performed [3H]Thymidine incorporation assay. Results are presented in 
Fig. 9A. Another purpose, was to investigate the contribution of S1P3 to 
migration of mMC by using adapted Boyden chamber assay (data not shown).  
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Abstract 
Both of the sphingosine kinase (SK) subtypes SK-1 and SK-2 catalyse the 
production of the bioactive lipid molecule sphingosine-1-phosphate (S1P). 
However, the subtype-specific cellular functions are largely unknown. In this 
study, we investigated the cellular function of SK-2 in primary mouse renal 
mesangial cells (mMC) and embryonic fibroblasts (MEF) from wild-type 
C57BL/6 or SK-2 knockout (SK2ko) mice. We found that SK2ko cells 
displayed a significantly higher proliferative and migratory phenotype when 
compared to wild-type cells, with concomitant increased cellular activities of 
the classical ERK and PI3K/Akt cascades, and of the small G protein RhoA. 
Furthermore, we detected an upregulation of SK-1 protein and S1P3 receptor 
mRNA expression in SK-2ko cells. The MEK inhibitor U0126 and the S1P1/3 
receptor antagonist VPC23019 blocked the increased migration of SK-2ko cells. 
Additionally, S1P3ko mesangial cells showed a reduced proliferative behaviour 
and reduced migration rate upon S1P stimulation, suggesting a crucial 
involvement of the S1P3 receptor. In summary, these data show that SK-2 
deficiency in renal mesangial cells and fibroblasts correlates with an enhanced 
capacity to proliferate and to migrate, indicating that SK-2 exerts suppressive 
effects on cell growth and migration. Obviously, therapeutic targeting of SKs 
for treating proliferative diseases essentially requires subtype-selective 
inhibitors.  
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3.1. Introduction 
One major function of sphingolipids is the structural support of cellular 
membranes. However, it has become clear that some sphingolipid subspecies 
also exert important signaling functions and thereby regulate a variety of 
physiological and pathophysiological processes including cell growth and 
differentiation, cell survival, migration and inflammation [1–4]. 
Especially ceramide and sphingosine 1-phosphate (S1P) have attracted a 
lot of interest, as they build a cellular rheostat that finally determines whether a 
cell grows or dies [2–4]. These two lipids are rapidly interconverted by the 
action of two enzyme classes, i.e. the ceramidases that deacylate ceramide to 
form sphingosine, and sphingosine kinases (SK) that phosphorylate sphingosine 
to form S1P.   
So far, two subtypes of SK, SK-1 and SK-2, have been cloned and 
characterized [5]. Both subtypes of SK are ubiquitously expressed in most 
tissues, but show differential subcellular localizations [5]. Although both 
enzymes catalyse the same reaction and produce S1P, the physiological or 
pathophysiological functions of the two subtypes and variants are presently not 
completely clear. Many studies have addressed the functions of SK-1 and there 
is a broad consent on its key function in cell proliferation and migration [6,7]. 
This is further supported by studies showing an up-regulation of SK-1 mRNA in 
several tumors [1,7,8]. Moreover, an increased SK-1 expression correlates with 
poor survival of breast cancer patients [9]. 
In contrast, SK-2 has been appointed a rather pro-apoptotic function 
based on cellular transfection experiments [10]. SK-2 contains a BH3 domain 
which can interact with Bcl-XL and thereby inhibit the protective potential of 
Bcl-XL consequently resulting in enhanced cell apoptosis. Additionally, the 
overexpression of SK-2 in various murine and human cell lines resulted in 
reduced DNA synthesis [11,12]. In line with this, previous data on mouse 
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mesangial cells isolated from SK-2 knockout mice revealed that lack of SK-2 
protected from stress-induced apoptosis [13]. However, recently it was 
suggested that also SK-2 positively contributes to cancer cell growth, since the 
putative selective SK-2 inhibitor ABC294640 reduced cancer cell growth in 
vitro and also in a mouse xenograft model [14].  
In the present study, we have used mouse renal mesangial cells (mMC) 
and mouse embryonic fibroblasts (MEF) isolated from SK-2 deficient mice and 
investigated changes in cellular responses such as cell migration and 
proliferation. We show that the loss of SK-2 correlates with a higher 
proliferative and migratory phenotype of the cells. On the contrary, when using 
the putative SK-2 inhibitor ABC294640 a reduced proliferation rate of renal 
mesangial cells was seen which surprisingly, was also detected in SK-2ko cells, 
suggesting that this compound is non-specific and affects cell proliferation 
unrelated to SK-2 inhibition. On the molecular level, we found that SK-2 
depleted cells have a compensatory upregulated SK-1 protein expression, an 
increased activity of the small G protein RhoA, increased activities of the 
classical ERK and PI3K/Akt cascades, and a strongly upregulated S1P3 receptor 
expression which may all contribute to the increased cell migration and 
proliferation observed. 
 
3.2. Materials and methods 
3.2.1. Chemicals 
 [6-3H]methyl-thymidine (specific activity: 14.5 Ci/mmol was from 
American Radiolabeled Chemicals Inc., St. Louis, MO, US; the secondary anti-
rabbit and anti-mouse horseradish peroxidase-coupled antibodies, Hyperfilm 
MP, and the enhanced chemiluminescence (ECL) reagents were from GE 
Health Care Systems GmbH, Freiburg, Germany; sphingolipid standards for 
LC/MS, W146, JTE-013 and VPC23019 were from Avanti Polar Lipids Inc., 
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Alabaster, AL, US; U0126, and wortmannin were from Merck Biosciences, 
Schwalbach, Germany; antibodies against phospho-Ser473-PKB/Akt,  phospho-
ERK1/2, total Akt, and total ERK1/2 were from Cell Signaling, Frankfurt, 
Germany; the ȕ-actin (clone AC-15) antibody, DAPI, were from Sigma Aldrich 
Fine Chemicals, St. Louis, U.S.; RhoA G-lisa was from Cytoskeleton Inc., CO, 
US; all cell culture media and supplements were from Invitrogen, Allschwil, 
Switzerland.  
3.2.2. Peptide synthesis and antibody generation for SK-1 and SK-2 
antibodies 
Peptide synthesis and antibody generation was performed by Eurogentec 
s.a. (Seraing, Belgium). Two synthetic peptides based on the sequence of the 
mouse SK-1 (accession number: NM_011451) (-CPS GRD SRR GPP PEE P-
COOH and –LEP RSQ-RGV FSV DGE C-CONH2) or on the sequence of the 
mouse SK-2 (accession number: NM_020011) (-CTL LTG PAG QKP QA-
COOH and -CPI AEG PPE MPA SSG F-CONH2) were synthesized and 
coupled to keyhole-limpet hemocyamin, and used to immunize two rabbits. The 
antibodies from terminal bleeds were purified by affinity chromatography by 
using an anti-peptide-coupled sepharose column.  
3.2.3. Cell culturing  
Primary cultures of mouse renal mesangial cells were isolated from 
C57BL/6 mice (Wt) or SK-2 knockout (ko) mice exactly as previously 
described [13,15]. Outgrown mesangial cells were subcultured and further used 
up to passage 20. Cells were cultured in RPMI medium containing 15% fetal 
bovine serum (FBS), 10 mM HEPES, pH 7.4, 100 units/ml penicilline, 
100 μg/ml streptomycin, 6 μg/ml bovine insulin, 5 μg/ml transferrin, 5 ng/ml 
sodium selenite, 4.5 μg/ml ȕ-mercaptoethanol. Mouse embryonic fibroblasts 
(MEF) were isolated from C57BL6 mice or SK-2 deficient mice as previously 
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described (Conner, 2001). Cells were cultured in Dulbecco’s modified Eagle 
medium (DMEM) containing 10% FBS, 10 mM HEPES, pH 7.4, 100 units/ml 
penicilline, 100 μg/ml streptomycin.  
3.2.4. siRNA transfection  
siRNA transfection was conducted by using the Amaxa™ Mouse/Rat 
Hepatocyte Nucleofector™ Kit (Lonza, Cologne, Germany) according to the 
Amaxa™ protocol for mouse embryonic fibroblasts. Briefly, mouse mesangial 
cells were harvested by trypsinization, centrifuged and resuspended in 100 µl 
Nucleofector™ solution. After addition of either 0.5 µM non-target siRNA 
(Thermo Fisher Scientic, Waltham, MA, USA) or 0.5 µM SK-2 siRNA 
(antisense sequence: GCC CUA CAC AUA CAG CGA C) transfection was 
perfomed in a cuvette using protocol N-024. The cells were immediately 
transferred to the culture plate and cultured at 37°C for 1-2 days prior to further 
experiments. 
3.2.5. Cell stimulation and Western blot analysis  
Confluent cells in 100 mm-diameter dishes were rendered quiescent by 
incubating for 24 h in DMEM containing 0.1 mg/ml of fatty acid-free bovine 
serum albumin (BSA). Thereafter, cells were treated as indicated. To stop the 
stimulation, the medium was withdrawn and the cells were homogenized as 
previously described [16]. Equal amounts of protein were separated by SDS-
PAGE and transferred to nitrocellulose membranes and subjected to Western 
blot analysis as previously described [16]. 
3.2.6. Transwell migration assay   
Cell migration was measured by an adapted Boyden chamber assay. In 
brief, the ability of cells to migrate through a Transwell filter (6.5 mm diameter, 
8μM pore size) was analysed. After serum starvation, cells were detached by 
trypsinization and seeded into transwell filters at 1 x 105 cells in 100 μl 
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starvation medium. 500 μl of starvation medium was placed in the lower 
compartment, and the cells were left to migrate for the indicated time periods. 
Thereafter, the Transwell filters were removed and processed exactly as 
previously described [17]. Migrated cells were determined by counting the 
DAPI-stained cells on the filters in five random areas per sample using a 
fluorescence microscope.  
3.2.7. Scratch assay for cell migration 
 Equal number of cells were seeded in growth medium in PS35 and 
cultured for 6 h to allow adherence followed by a starvation period in DMEM 
containing 1% of FBS for 18 h. Thereafter, a “scratch” was created on the 
confluent cell monolayer using a p200 pipet tip and the dish was immediately 
photographed under a phase-contrast microscope at specific reference points. A 
second image was taken 24 h after previous alignment along the reference 
points to ensure assessment of the same scratch area. The images were analysed 
using the Image J software (Wayne Rasband, NIH, USA) by measuring the 
scratch area at 0 h and 24 h after incubation. Data are expressed as area 
reduction from time points 0 to 24 h.  
3.2.8. [3H]Thymidine incorporation 
 5000 cells were plated per well of a 24-well plate and incubated for 20 h. 
Thereafter, cells were incubated in growth medium containing 0.2 µCi/ml of 
[3H] methyl-thymidine. After different time periods, the medium was removed 
and cells were washed twice with PBS, and incubated with ice-cold 5% 
trichloroacetic acid (TCA) for 30 min. Cells were washed twice with 5% TCA 
and the DNA was solubilized in 1 M NaOH for 30 min at 37°C, and the 
radioactivity was counted in a ȕ-counter. 
3.2.9. Quantitative PCR analysis 
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Real-time PCR was performed using SYBRgreen® and a BioRad iQ 
iCycler Detection System. Primer sequences were as follows in table 3.1.  
Table 3.1. Characteristic of primers used for qPCR analysis 
Gene Forward primer (from 5’ to γ’) 
Reverse primer (from 5’ to γ’)  
mouse S1P1 CTGACCTTCCGCAAGAACATCT 
CTTCAGCAAGGCCAGAGACTTC 
mouse S1P2 GAGCTCATCACCTCTTCATCCTATC 
GAAGATGCAGTAAGAGTACCCAGGA 
mouse S1P3 TGTAGCTTCATCGTCGTCTTGGAG 
GCCGATGAAAAAGTACATGCGG 
mouse S1P4 GGCTACTGGCAGCTATCCTG 
AAGGCCACCAAGATCATCAG 
mouse S1P5 GGAGGGACTCTCCTGGATTC 
TTCCTCTGTAGCCAGCCACT 
 
IQTM5 Optical System Software (Version 2.0) was used to analyze real 
time and endpoint fluorescence. One microgram of total RNA isolated with 
TRIZOL® reagent was used for reverse transcriptase–PCR (First Strand 
Synthesis Kit, MBI Fermentas, St-Leon-Roth, Germany); a random hexamer 
primer was utilized for amplification. The fold induction values were obtained 
according to the ΔΔCT method, after normalization to the housekeeping gene 
18S RNA. 
3.2.10. RhoA activity assay 
 The activity of the small G protein RhoA was determined by using a 
specific G-LISA™ activity assay kit (Cytoskeleton Inc., Denver, CO, US) 
exactly as described in the manufacturer’s manual.  
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3.2.11. Lipid quantification by mass spectrometry  
Confluent cells in PS35 wells were either taken for lipid extraction and 
LC-MS/MS analysis exactly as previously described [13] or taken for cell 
counting for lipid equalization. 
3.2.12. Statistical analysis  
Statistical analysis was performed by unpaired t-test and two-tailed p 
values for the comparison of two groups, and by one-way analysis of variance 
(ANOVA) with Bonferroni post test for the comparison of three and more 
groups. 
 
3.3. Results 
3.3.1. Loss of SK-2 leads to increased proliferation and migration of 
mouse mesangial cells and fibroblasts. 
Since the cellular function of SK-2 is still poorly understood, we here 
used renal mesangial cells and mouse embryonic fibroblasts isolated from either 
wild-type mice or SK-2 gene deficient mice to unravel a possible contribution 
of SK-2 to physiological or pathophysiological cell responses. First, renal 
mesangial cells (Fig. 1A) and mouse embryonic fibroblasts (Fig. 1B) were 
characterized for SK-2 protein expression by Western blot analysis. SK-2 runs 
as an approx. 68 kDa band in SDS-PAGE. In primary cultures of mMCs or 
MEFs isolated from SK-2 knockout (ko) mice, this band was abolished 
confirming the complete knockout of the gene. The antibody additionally 
recognized a band at 43 kDa, which was not reduced in the SK-2 depleted cells, 
thus suggesting a likely unspecific staining.  
Under normal cell culturing conditions, it became very obvious that SK-
2ko cells proliferated much faster than the corresponding wild-type cells. To 
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confirm that DNA synthesis was enhanced, [3H] thymidine incorporation was 
measured in cells plated in equal numbers. As seen in Fig. 2A, over the time 
period of 2 days, SK-2ko mMC showed a several fold increase of DNA 
synthesis. A similar increase was also seen in SK-2ko MEFs when compared to 
the wild-type cells (Fig. 2B) and in mesangial cells that were transiently 
transfected with siRNA against SK-2 (Fig. 2C). Additionally, we tested the 
putative SK-2 inhibitor ABC294640 on renal mesangial cell proliferation and 
detected a reduction of cell proliferation at a concentration of 30 µM and even 
more pronounced at 100 µM. Strikingly, the same effect was obtained when 
using SK-2 knockout mesangial cells (Fig. 2D, grey bars) suggesting an 
unspecific effect of ABC294640 not related to SK-2 inhibition. 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Sphingosine kinase 2 protein expression in mouse renal mesangial cells and embryonic 
fibroblasts. Protein lysates of quiescent mouse mesangial cells (mMC) and mouse embryonic 
fibroblasts (MEF) isolated from either C57BL/6 mice (Wt), SK-1 deficient mice (SK-1ko), or SK-2 
deficient mice (SK-2ko), or rat mesangial cells (rMC) were separated by SDS-PAGE, transferred to 
nitrocellulose and subjected to Western blot analysis using a specific antibody against mouse SK-2 at 
a dilution of 1:1000. Bands were visualised by the ECL method according to the manufacturer’s 
instructions.  
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Fig.2. Effect of SK-2 deficiency on proliferation of mouse mesangial cells and embryonic 
fibroblasts. 104 mouse mesangial cells (A, C, D, mMC) or mouse embryonic fibroblasts (B, MEF) 
isolated from either wild-type C57BL/6 mice (Wt, open circles) or SK-2 deficient mice (SK-2ko, 
closed circles) or mesangial cells transiently transfected with a non-target siRNA (C, NT-siRNA, 
open circles) or siRNA against SK-2 (C, siSK-2, closed circles) were plated and grown for the 
indicated time periods in growth medium supplemented with [3H]thymidine alone (A, B, C) or with 
the indicated concentrations of ABC294640 for 24 h (D) and processed as described in the Methods 
Section. [3H]thymidine incorporated into DNA was measured in a ȕ-counter. Data are expressed as 
cpm/well (A, B) or % of control (C, D) and are means ± S.D. (n=3-5). *p<0.05, **p<0.01, 
***p<0.001 considered statistically significant compared to the corresponding Wt values (A, B) or to 
the respective control values (C, D). 
 
In a next step, the migratory capacity of cells was determined. For this, 
either an adapted Boyden chamber assay (Fig. 3A), or a scratch assay (Figs. 3B- 
G) was performed. In the adapted Boyden chamber assay, equal numbers of 
cells were plated onto a transwell filter with 8μm pores and were allowed to 
migrate through the filter for 7h. Thereafter, non-migrated cells were scraped  
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Fig. 3: Effect of SK-2 deficiency on migration of mouse mesangial cells and embryonic 
fibroblasts. (A) 105 serum-starved mouse mesangial cells or mouse embryonic fibroblasts isolated 
from either wild-type (Wt) or SK-2 deficient mice (SK-2ko) were subcultured onto transwell filters 
and allowed to migrate for 7h. Migrated cells were determined as described in the Methods Section. 
(B - G) Quiescent cells were subjected to a scratch and then allowed to recover for 24 h in DMEM 
containing 1% FBS. Light microscopy pictures were taken at time point 0 h and 24 h after the scratch. 
Data in C, E, G show the quantification of the scratch and are expressed as invaded area from time 
point 0 h to 24 h as % of the Wt or NT-siRNA control and are means ± S.D. (n=6-9). ***p<0.001 
considered statistically significant compared to the Wt or the NT-siRNA control. 
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away from the surface of the filter and cells that had migrated into the filter 
were visualised by DAPI staining. Fig. 3A shows that again, SK-2ko cells 
migrated faster than wild-type cells. Another method to measure cell migration 
is the so-called scratch assay. However, this assay can not discriminate between 
migrating cells and proliferating cells and results reflect more a mixture of 
migration and proliferation. Therefore, to minimize the amount of cell 
proliferation, we performed this assay under strongly reduced serum 
concentrations (1% FBS). Again, our data revealed that SK-2ko mesangial cells 
(Fig. 3B, right panels) and SK-2ko MEFs (Fig. 3D, right panels) or cells 
transfected with siRNA against SK-2 (Fig. 3F, right panels) migrated faster than 
the corresponding wild-type (Figs. 3B and 3D, left panels) or non-target siRNA 
transfected cells (Fig. 3F, left panels). 
3.3.2. Loss of SK-2 leads to activation of ERK and Akt signalling in 
mesangial cells and fibroblasts 
We further investigated whether the increased proliferation and migration 
of SK-2ko cells was due to specifically activated signaling cascades such as the 
well known proliferation and migration regulating classical mitogen-activated 
protein kinase (MAPK)/extracellular signal regulated kinase (ERK) cascade. To 
this end, Western blot analyses of mesangial cell lysates were performed by 
staining for phosphorylated and thus activated p44-ERK1 and p42-ERK2. 
Quiescent wild-type cells which were incubated for 6 h in a very low serum 
concentration (1% FBS) expressed low levels of phospho-ERK1/2, whereas the 
SK-2ko cells showed a significantly increased ERK1/2 phosphorylation (Fig. 
4A). Another signaling cascade that has been linked to cell growth and survival, 
but also to cell migration, is the PI3K/Akt cascade [18]. We found that also 
phospho-Akt was enhanced in SK-2ko mesangial cells (Fig. 4B). Similar data 
were obtained in MEFs (Fig. 4C and 4D). All these data suggest that in SK-2ko 
cells, the classical MAPK/ERK and the PI3K/Akt cascades are hyperactivated. 
Chapter 3. SK-2 deficiency in non-cancer cells correlates with enhanced proliferation and migration 
85 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4: Effect of SK-2 deficiency on the activation state of ERK1/2 and PKB/Akt in mouse 
mesangial cells and fibroblasts. Quiescent mouse mesangial cells (A and B) and mouse embryonic 
fibroblasts (C and D) isolated from either wild-type (Wt, white bars) or SK-2 deficient mice (SK-2ko, 
grey bars) were incubated for 6 h in DMEM containing 1% FBS. Thereafter, cell lysates containing 
50 µg of protein were separated by SDS-PAGE, transferred to nitrocellulose and subjected to Western 
blot analysis using antibodies against phospho-ERK1/2 and total ERK1/2 (A and C), and phospho-
Ser473-PKB/Akt and total PKB/Akt1 (B and D). Bands were visualized by the ECL method according 
to the manufacturer’s instructions and bands were densitometrically evaluated. Data are expressed as 
% of controls and are means ± S.D. (n=3). *p<0.05, **p<0.01, ***p<0.001 considered statistically 
significant compared to the corresponding Wt values. The insets show the corresponding 
immunoblots. 
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Fig. 5: Involvement of the PI3K and ERK pathway in the SK2ko-mediated increased migration 
and proliferation in mesangial cells. (A) Quiescent wild-type (Wt, white bar)) or SK-2 deficient 
(SK-2ko, grey bars) mesangial cells (mMC) were subjected to a scratch and then allowed to recover 
for 24 h in DMEM containing 1% FBS in the absence (Ctrl) or presence of wortmannin (200 nM) or 
U0126 (10 µM). Light microscopy pictures were taken at time point 0 h and 24 h after the scratch and 
analysed using the Image J software (Wayne Rasband, NIH, USA) by measuring the scratch area. 
Data are expressed as area reduction from time points 0 h to 24 h as % of the Wt control and are 
means ± S.D. (n=4). (B) Wild-type (Wt, white bars) or SK-2 deficient (SK-2ko, grey bars) mesangial 
cells (mMC) were plated and grown for the indicated time periods in growth medium supplemented 
with [3H]thymidine alone (Ctrl) or in the presence of wortmannin (200 nM) or U0126 (10 µM) and 
processed as described in the Methods Section. [3H]thymidine incorporated into DNA was measured 
in a ȕ-counter. Data are expressed as cpm/well and are means ± S.D. (n=4-6). ***p<0.001 considered 
statistically significant compared the Wt ctrl, §§§p<0.001 considered statistically significant compared 
to the SK-2ko ctrl value. 
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To see whether the ERK and PI3K/Akt pathways, are involved in the 
increased migration and proliferation seen in Sk-2ko cells, we performed 
scratch assays and measured DNA synthesis of mouse mesangial cells in the 
absence or presence of inhibitors of these signalling pathways. Fig. 5A and 5B 
show that the specific MEK inhibitor U0126 [19,20], but not the PI3K inhibitor 
wortmannin [20] inhibited migration and proliferation of SK-2ko mMC.  
Furthermore, it is well known that small G proteins are important 
molecular regulators of cell migration and also proliferation [21]. We therefore 
investigated whether small G proteins are altered in SK-2ko cells. Small G 
protein activity was measured by G-LISA®, which specifically detect the 
activated forms of the indicated small G proteins [22]. As seen in Fig. 6, basal 
RhoA activity was significantly increased in SK-2ko mesangial cells and this 
was further enhanced after S1P treatment. By contrast Ras, Rac and cdc42 were 
not altered in SK-2ko mesangial cells (data not shown). 
 
 
 
 
 
 
Fig. 6: Effect of SK-2 deficiency on RhoA activity in mouse mesangial cells. Quiescent mouse 
mesangial cells isolated from either wild-type (Wt, white bars) or SK-2 deficient mice (SK-2ko, grey 
bars) were stimulated for 10 min with either vehicle (Ctrl) or sphingosine 1-phosphate (S1P, 1 µM) in 
the presence of 1% FBS. Thereafter, cell lysates were subjected to G-LISA® RhoA activation assay 
according to the manufacturer´s instructions. Data are expressed % of Wt ctrl and are means ± S.D. 
(n=3). **p<0.01, ***p<0.001 considered statistically significant compared to the vehicle treated Wt 
value, §§p<0.01 considered statistically significant compared to the S1P-stimulated Wt value. 
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3.3.3. Loss of SK-2 is associated with enhanced expression of SK-1 and 
the S1P3 receptor. 
In a next step, we tested both cell types for a possible compensatory 
upregulation of SK-1 expression. By using Western blot analysis, we indeed 
found an enhanced expression of SK-1 protein in SK-2ko mesangial cells and 
MEF. Even a partial and transient reduction of SK-2 with SK-2-siRNA resulted 
in a higher SK-1 protein expression compared to non-target siRNA transfected 
cells (Fig. 7A). Furthermore, we screened the cells for S1P receptor subtype 
expression and interestingly found that in SK-2ko mMCs (Fig. 7B) and MEFs 
(Fig. 7C), specifically the S1P3 was highly up-regulated on mRNA level. In 
addition, we quantified cellular S1P in the cells and found that SK-2ko MEF 
contain significantly more cellular S1P than the wild-type cells (Fig. 7E). 
Despite a similar upregulation of SK-1 protein in SK-2ko mesangial cells, the 
S1P concentration in mMCs did not vary between wild-type and SK-2ko cells 
(Fig. 7D). Sphingosine and C16-ceramide accumulated in SK-2ko cells in both 
cell types (Fig. 7D, E). To address if the altered S1P receptor expression profile 
had an impact on cell motility, we performed a scratch migration assay in the 
presence of the S1P receptor antagonists W146 (S1P1 antagonist), JTE-013 
(S1P2 antagonist) and VPC23019 (S1P1/3 antagonist). Our data revealed that a 
significant reduction of cell migration was only detected in SK-2ko cells when 
using the S1P1/3 inhibitor VPC23019, but not in the presence of W146, thereby 
excluding a role of S1P1 in the increased migration capacity of SK-2ko cells 
(Fig. 8). The S1P2 inhibitor JTE-013 enhanced the migratory response of wild-
type and SK-2ko cells, thereby demonstrating a potentially inhibitory role of 
S1P2 in mesangial cell migration (Fig. 8). These data make it tempting to 
speculate that the observed enhanced migration and proliferation of SK-2ko 
cells may be due to an autocrine S1P action through the S1P3 receptor, although 
a further increase of S1P levels in renal mesangial cells seems dispensable. 
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Fig. 7: Effect of SK-2 deficiency on SK-1 protein expression, S1P receptor subtype mRNA 
expression and on cellular sphingolipid levels in mouse mesangial cells and embryonic 
fibroblasts. ((A) Quiescent mouse mesangial cells and mouse embryonic fibroblasts isolated from 
either C57BL/6 mice (Wt) or SK-2 deficient mice (SK-2ko) or mouse mesangial cells transiently 
transfected with either non-target siRNA (NT-siRNA) or siRNA against SK-2 (siSK-2) were 
subjected to WB analysis using specific antibodies against SK-1 (upper panels), SK-2 (middle panels) 
or ȕ-actin (lower panels). (B–D) Quiescent mouse mesangial cells (B) and mouse embryonic 
fibroblasts (C) isolated from either C57BL/6 mice (Wt) or SK-2 deficient mice (SK-2ko) or 
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transiently transfected mouse mesangial cells with either non-target siRNA (D, NT-siRNA) or siRNA 
against SK-2 (D, siSK-2) were taken for RNA extraction and subjected to quantitative PCR analysis 
using mouse primers of S1P1-5 (B, C) or S1P3 (D) as described in the Methods section. Data were 
obtained according to the ΔΔCT method and are expressed as fold induction of S1P1 expression level 
(B, C) or as% of NT-siRNA (D) and are mean• }SD (n = 3–4). *p < 0.05, **p < 0.01, ***p < 0.001 
considered statistically significant compared to the corresponding Wt values. (E, F) Lipids were 
extracted from quiescent mouse mesangial cells (E) and mouse embryonic fibroblasts (F) from wild-
type (Wt, white bars) and SK-2 deficient mice (SK-2ko, grey bars) and taken for LC-MS/MS to 
quantify sphingosine 1-phosphate (S1P), sphingosine (Sph) and C16-ceramide (C16-Cer). Results are 
expressed as ng lipid per 106 cells and are mean• }SD (n = 3). *p < 0.05, **p < 0.01, ***p < 0.001 
considered statistically significant compared to the corresponding Wt values. 
 
 
 
 
 
 
 
 
Fig. 8: Effect of S1P receptor antagonists on the increased migration of mouse mesangial cells. 
Quiescent wild-type (Wt, white bars) or SK-2 deficient (SK-2ko, grey bars) mesangial cells (mMC) 
were subjected to a scratch and then allowed to recover for 24 h in DMEM containing 1% FBS in the 
presence of either vehicle (Ctrl) or VPC23019 (VPC, 10 µM), W146 (10 µM) or JTE-013 (JTE, 10 
µM). Light microscopy pictures were taken at time point 0 h and 24 h after the scratch and analysed 
using the Image J software (Wayne Rasband, NIH, USA) by measuring the scratch area. Data are 
expressed as area reduction from time points 0 h to 24 h as % of the Wt ctrl and are means ± S.D. 
(n=4). **p<0.01, ***p<0.001 considered statistically significant compared to the Wt ctrl, §§p<0.01 
considered statistically significant compared to the SK-2ko ctrl value. 
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Finally, we investigated the contribution of S1P3 to mesangial cell 
proliferation and migration by using cells isolated from S1P3 knockout mice. 
Data in Fig. 9A show that the growth of S1P3ko mMCs in normal growth 
medium containing 10% FBS was significantly but only partially reduced when 
compared to wild-type cells. When migration of these cells was analysed in a 
scratch assay, we found that stimulation of cells with S1P triggered increased 
migration in wild-type cells (Fig 9B), which was abolished in S1P3ko cells (Fig 
9B). Also the stimulation of RhoA activity by S1P detected in wild-type cells 
was clearly reduced in S1P3ko cells (Fig. 9C). Together these data suggest that 
indeed S1P3 is contributing to mesangial cell proliferation and migration.  
 
3.4. Discussion 
In this study we show for the first time that renal mesangial cells and 
embryonic fibroblasts isolated from SK-2 deficient mice have a higher capacity 
to proliferate and migrate when compared to wild-type cells. Since the 
successful cloning of SK-2 in 2000 [23], the few published studies have 
reported rather controversial data on possible cellular functions of SK-2. On 
the one hand, overexpression studies in various cell types revealed that SK-2 is 
localised in the nucleus and can inhibit DNA synthesis [11]. Moreover, Liu et 
al. reported that overexpression of SK-2 had a pro-apoptotic effect on cells due 
to the existence of a BH3 domain which interacts with the anti-apoptotic factor 
Bcl-XL and thereby blocks Bcl-XL’s anti-apoptotic function [10]. In line with 
this, our own previous studies revealed that a loss of SK-2 rendered mesangial 
cells less sensitive to stress-induced apoptosis [13]. 
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Fig. 9: Effect of S1P3 knockout on 
proliferation and migration of 
mouse mesangial cells. (A) 105 
mesangial cells isolated from either 
BalbC mice (Wt) or S1P3-deficient 
mice (S1P3ko) were plated and 
proliferation assay was processed as 
described in the Methods Section. 
[3H]thymidine incorporated into DNA 
was measured in a ȕ-counter. Data are 
expressed as cpm/well and are means 
± S.D. (n=3). *p<0.05, ***p<0.001 
statistically significant compared to 
the corresponding control values. (B) 
Quiescent control mouse mesangial 
cells or S1P3-deficient mesangial cells 
were subjected to a scratch and 
allowed to recover for 24 h in DMEM 
containing 1% FBS the presence of 
either vehicle (Ctrl) or S1P (1 µM). 
Light microscopy pictures were taken 
at time point 0 h and 24 h after the 
scratch and analysed. Data are 
expressed as area reduction from time 
points 0 h to 24 h as % of the Wt ctrl 
value and are means ± S.D. (n=4-6). 
**p<0.01 statistically significant 
compared to the Wt ctrl value. (C) 
Quiescent mouse mesangial cells 
isolated from either BalbC mice or S1P3-deficient mice were stimulated for 10 min with either vehicle 
(Ctrl) or sphingosine 1-phosphate (S1P, 1 µM) in the presence of 1% FBS. Cell lysates were subjected 
to G-LISA® RhoA activation assay according to the manufacturer´s instructions. Data are expressed 
% of Wt ctrl value and are means ± S.D. (n=4). *p<0.05, ***p<0.001 considered statistically 
significant compared to the vehicle treated Wt value, §§§p<0.001 considered statistically significant 
compared to the S1P stimulated Wt value. 
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On the other hand, SK-2 was activated by epidermal growth factor 
(EGF) [24] due to ERK-mediated hyperphosphorylation in breast cancer cells. 
Such an activation of SK-2 by growth factors is hardly consistent with a growth 
inhibiting and pro-apoptotic effect of SK-2. In fact, we previously showed that 
in the breast cancer cell line MCF-7, EGF and estrogen rather down-regulated 
SK-2 mRNA expression [25,26] which occurred concomitantly to an up-
regulation of SK-1 by these factors.  
Recently, a catalytic inhibitor of SK-2 ABC294640 [27] was developed 
and used to address the cellular function of SK-2. Although the in vitro IC50 for 
SK-2 was rather high at 50 μM [14], oral administration of ABC294640 to 
mice bearing mammary adenocarcinoma xenografts resulted in a dose-
dependent antitumor activity associated with depletion of S1P levels in the 
tumours and progressive tumour cell apoptosis [14,28]. These data suggested 
that SK-2 similar to SK-1 is also positively involved in cancer growth and 
progression. In our present study, treatment of mesangial cells with 30 and 
100 µM ABC294640 resulted in a reduced proliferation rate, which however, 
was also detected in SK-2ko cells (Fig. 2C). These data clearly demonstrate 
that ABC294640 elicits an anti-proliferative effect independent of SK-2 
inhibition, thereby questioning the specificity of ABC294640. Recently, 
ABC294640 was shown to exert anti-estrogenic effects by directly 
antagonising estrogen receptor (ER) activation [27]. Molecular modeling 
studies revealed a direct docking of ABC294640 into the ligand binding site of 
the ERα. This estrogen antagonistic potential may explain on the one hand the 
anti-proliferative effect and on the other hand why especially estrogen-sensitive 
breast cancer cells were strongly affected by the compound. The comparison of 
in vivo effects of ABC294640 with the effect of genetic SK-2 knockout mice 
also revealed inconsistent results. Whereas the inhibitor aggravated 
inflammatory arthritis, the SK-2 knockout mice showed no change of disease 
severity compared to wild-type mice [29]. Moreover, Liang et al. showed that 
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SK-2 deficient mice develop more severe chronic intestinal inflammation and 
colitis-associated cancer which in terms of mechanism, was proposed to 
involve a counter-upregulation of SK-1 and S1P [30]. 
Also our study showed a compensatory up-regulation of SK-1 protein in 
SK-2ko cells and SK-2-siRNA transfected cells. However, using LC-MS/MS 
we only detected a rise of cellular S1P in SK-2ko MEF but not in SK-2ko 
mMCs. The reason for this discrepancy might be due to a detection limit, since 
we only measured S1P in whole cell lipid extracts but not in subcellular 
fractions. Another possibility is that produced S1P is secreted more efficiently 
from mesangial cells than from fibroblasts. However, so far we are not able to 
measure an increased level in cell culture supernatants (data not shown). Thus, 
further experiments are needed to clarify this issue.  
In addition, our data revealed that specifically the S1P3 receptor was up-
regulated upon loss of SK-2 (Fig. 7A and 7B). We therefore speculate that 
increased proliferation and migration observed in SK-2ko cells may be due to 
this enhanced S1P3 expression. We obtained evidence that S1P3 is involved in 
mesangial cell migration and proliferation from S1P3 knockout mesangial cells 
as (i) the S1P3ko cells showed a slower proliferation rate in comparison to wild-
type cells (Fig. 9A) and (ii) S1P was able to induce cell migration only in wild-
type but not in S1P3ko cells (Fig. 9B). However, since mesangial cell 
proliferation was only partially reduced in S1P3-deficient cells and also showed 
normal migration behaviour under control conditions, we conclude that other 
receptor subtypes may also be involved. Katsuma et al. reported that 
extracellular S1P triggers mesangial cell proliferation by involving both S1P2 
and S1P3 [31]. Similarly, proliferation of hepatoma cells [32] and satellite cells 
[33] also depended on both S1P2 and S1P3. Concerning cell migration, we 
observed an increased migration of mesangial cells when inhibiting the S1P2 
receptor with JTE013, suggesting a potentially inhibitory role of S1P2 in cell 
migration, which was previously also reported in other cell types [34–36]. 
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Similar to S1P2 also the involvement of S1P3 in a migratory event is 
conflicting. In this respect, Okamoto et al. showed that an overexpression of 
S1P1 and S1P3 in Chinese hamster ovary (CHO) cells resulted in more S1P-
stimulated migration [37]. A similar situation was reported for human 
endothelial cells where S1P-triggered migration was abolished by antisense 
oligonucleotides against S1P1 and S1P3 [38] and in lung cancer cells where 
either a S1P3 knockdown by RNAi or Rho kinase inhibition by a catalytic 
inhibitor prevented a S1P-stimulated migratory/invasive response [39].  
By generating S1P receptor knockout mice, it turned out that S1P1 
deficient mice are embryonically lethal since vascular maturation failed due to a 
defect in smooth muscle cells migration [40] and consistently, embryonic 
fibroblasts (MEF) isolated from these S1P1 deficient mice also exhibited a 
defect in chemotaxis towards S1P [40]. These data clearly support an in vivo 
relevant function of S1P1 in smooth muscle cell and fibroblast migration. In 
contrast, S1P3 deficient mice showed no vascular maturation deficit which 
indirectly allowed the conclusion that S1P3 is not involved in smooth muscle 
cell migration and consequently vessel maturation [40,41]. All these data do not 
allow a general conclusion, but somehow stress the possibility that S1P3, 
eventually in cooperation with S1P1, is involved in S1P-stimulated cell 
migration in a cell-type specific manner. 
Our data further demonstrate that not only the basal but also the S1P-
stimulated RhoA activity is enhanced in SK-2 deficient cells. RhoA is one of 
three members of the Rho GTPase family that is known to play a crucial role in 
the regulation of cell migration. There seems to be a spatiotemporal dynamic of 
RhoA action that drives not only membrane protrusions at the leading edge of 
the cells but also drives tail retraction [42]. Although previously regarded as an 
anti-migratory GTPase, the finding that RhoA localises at the leading edge of 
cells where it is important for membrane ruffling and lamellae formation 
supported a series of studies describing RhoA as pro-migratory factor [for 
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review see: 43]. As we were only able to measure RhoA activity in whole cell 
lysates, we cannot decipher the exact cellular localisation of the enhanced RhoA 
activity in SK-2ko cells to allow a final conclusion on the specific impact of 
RhoA acting pro-migratory on the leading edge or anti-migratory by tail 
retraction in mesangial cells. However, RhoA is activated by extracellular S1P 
in many cell types including CHO cells [37], endothelial cells [38], and bladder 
cancer cells [44], and this seems to be mandatory for cell migration. It is 
tempting to speculate that both S1P2 and S1P3 receptors may cooperatively 
orchestrate cell migration. All these data suggest that it is well conceivable that 
an enhanced SK-1/S1P3/RhoA signalling may contribute to the increased 
migration in SK-2ko cells. 
Notably, in SK-2ko cells there was a much more pronounced increase of 
sphingosine and C16-ceramide than of S1P (Fig. 7C, D) supporting speculations 
whether another sphingolipid mediator besides S1P may contribute to the 
observed effects in this study. In this regard, we and others have shown that 
ceramide can directly bind to and activate c-Raf [45], PKCα [46] and PKC-ζ 
[47]  but inhibit PKC-δ [46,48]. Future studies are necessary to evaluate the 
exact contribution of the various sphingolipid-derived mediators to the observed 
phenotype of SK-2ko mesangial cells. 
Although our study has only addressed the effect of SK-2ko on the 
cellular level on mesangial cells, it will be interesting to see whether in vivo in a 
renal disease model SK-2 deficient mice also respond with increased 
proliferation and migration. In this context, it was reported in a renal 
ischemia/reperfusion injury (IRI) model, that loss of SK-2 led to more severe 
kidney injury as indicated by elevated plasma creatinine levels, increased 
tubular cell necrosis, dilation of tubules, and cast formation in the outer medulla 
of SK-2ko mice. In addition, kidneys of IRI-exposed SK-2ko mice not only 
showed more neutrophil infiltration but remarkably also increased S1P3 
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expression [49] which resembled our data obtained in renal mesangial cells and 
fibroblasts. 
Altogether, these data show for the first time that a loss of SK-2 in renal 
mesangial cells and fibroblasts may have a considerable impact on cell growth 
and migration and that SK-2 exerts a suppressive effect on these cellular 
responses that are crucial in many renal diseases such as renal cancer and 
chronic inflammatory kidney diseases.  
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In this project I participated in studying of effectiveness of AVX001 and 
AVX002 compounds for reduction of cytokine-stimulated PGE2 formation in 
mesangial cells (Fig. 4).   
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Abstract 
Omega3-polyunsaturated fatty acids (ω3-PUFA) are known to exert anti-
inflammatory effects in various disease models although the direct targets are 
only poorly characterized. Here we report on two new cPLA2 inhibitors, the ω 
3-derivatives 1-octadeca-2,6,9,12,15-pentaenylsulfanyl-propan-2-one 
(AVX001) and 1-octadeca-3,6,9,12,15-pentaenylsulfanyl-propan-2-one 
(AVX002) and their effects on inflammatory prostaglandin E2 (PGE2) 
production in cultures of renal mesangial cells. AVX001 and AVX002 dose-
dependently inhibited the group IVA cytosolic phospholipaseA2 (cPLA2) in an 
in vitro activity assay with a calculated IC50 value of 112 nM for AVX001 and 
131 nM for AVX002 whereas the known cPLA2 inhibitor arachidonoyl 
trifluoromethyl ketone (AACOCF3) was less potent and docosahexaenoic acid 
(DHA) was inactive. In renal mesangial cells, AVX001 and AVX002 
suppressed interleukin-1ȕ (IL-1ȕ)-induced PGE2 synthesis. Mechanistically, this 
effect occurred by a downregulation of IL-1ȕ-induced group IIA-sPLA2 protein 
expression, mRNA expression and promoter activity. A similar but less potent 
effect was seen with AACOCF3 and no effect was seen with DHA. Since gene 
expression of sPLA2 is known to be regulated by the transcription factor nuclear 
factor κB (NFκB), we further investigated NFκB activation. Both compounds 
prevented NFκB activation by blocking degradation of the inhibitor of κB (IκB). 
These data show for the first time that the novel cPLA2 inhibitors AVX001 and 
AVX002 exerted an anti-inflammatory potential in cultures of renal mesangial 
cells and reduced the pro-inflammatory mediator PGE2 through an inhibitory 
effect on NFκB activation. Therefore, these compounds may represent 
promising novel drugs for the treatment of inflammatory disorders. 
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4.1. Introduction 
Mesangial cells are specialized smooth muscle-like cells located in the 
renal glomerulus and are not only involved in the regulation of the glomerular 
filtration rate and in the preservation of the structural integrity of the 
glomerulus, but also play a central role in most pathological processes of the 
renal glomerulus [1,2]. Upon activation by a variety of pro-inflammatory 
cytokines, mesangial cells respond with three prominent reactions which are all 
hallmarks of many forms of glomerulonephritis: (i) increased proliferation, (ii) 
increased mediator production including cytokines and chemokines, nitric 
oxide1 (NO) and superoxide radicals, and prostaglandins (PG), and (iii) 
increased extracellular matrix production [1]. The detailed mechanisms 
underlying these cell responses are still not completely understood.  
One important event in the inflammatory reaction and the rate-limiting 
step in the generation of prostaglandins is the activation of a phospholipase A2 
(PLA2) which hydrolyzes the sn-2 ester bond of substrate phospholipids and 
thereby generates arachidonic acid and lysophospholipids [3]. Arachidonic acid 
is then further converted by either cyclooxygenases or lipoxygenases and 
downstream enzymes to the eicosanoids including prostaglandins, 
thromboxanes and leukotrienes. 
So far, 15 groups and many subgroups of PLA2s have been identified 
which include five distinct types of enzymes, i.e. secreted PLA2s (sPLA2), the 
cytosolic PLA2s (cPLA2), the Ca2+-independent PLA2s (iPLA2), the platelet-
activating factor acetylhydrolases (PAF-AH), and the lysosomal PLA2s [3].  
Since cPLA2 preferentially hydrolyses arachidonic acid-containing 
phospholipids at the sn-2 position, this enzyme is thought to be one key enzyme 
in inflammatory eicosanoid formation.  
In renal mesangial cells, four PLA2 subtypes are expressed either 
constitutively or inducibly. These include the cPLA2, the iPLA2, and the group 
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IIA and V sPLA2 [4–7]. In previous studies on mesangial cells, it was shown 
that the drastic increase of cytokine-triggered PGE2 formation involved both 
IIA-sPLA2 and cPLA2 activation [8]. By using the specific sPLA2 inhibitor 
CGP43187 or by using a neutralizing antibody against IIA-sPLA2, about 80 % 
of the cytokine-triggered PGE2 formation was depleted suggesting that the 
remaining small amount of approx. 20 % of PGE2 derives from cytokine-
stimulated cPLA2 activity [8]. Indeed, the cPLA2 is not only acutely activated 
by interleukin 1 (IL-1) [5], but also upregulated upon prolonged IL-1 treatment 
by a transcriptional mechanism [4,9]. Furthermore, a cross-communication 
exists between the different PLA2s. Thus, in mesangial cells, we previously 
showed that the IIA-sPLA2, acting from the outside of cells, is able to activate 
the cPLA2 intracellularly via a protein kinase C (PKC) and mitogen activated 
protein kinase (MAPK) dependent mechanism [10]. In mouse P388D1 
macrophages, it was shown that cPLA2 also contributes to V-sPLA2 activation 
[11]. All these data suggest that the different PLA2s regulate each other and are 
critically participating in pro-inflammatory PGE2 formation. 
In this study we have identified and characterized two novel direct cPLA2 
inhibitors, i.e. the ω3-PUFA derivatives AVX001 and AVX002. We show that 
in cultures of renal mesangial cells, AVX001 and AVX002 downregulated 
cytokine-stimulated PGE2 formation through a mechanism blocking cytokine-
triggered and cPLA2-dependent NFκB activation and subsequent gene 
transcription of sPLA2. These data suggest that AVX001 and AVX002 could 
serve as novel anti-inflammatory drugs. 
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4.2. Materials and methods 
4.2.1. AVX001 and AVX002  
Both compounds were synthesized and characterized according to 
Holmeide and Skattebol (2000) [12] and kindly provided by Dr. Inger Reidun 
Aukrust and Dr. Marcel Sandberg (Synthetica AS, Norway). The chemical 
structures are indicated in Fig. 1.  
 
 
 
 
 
 
 
 
 
 
Fig. 1. Chemical structure of various cPLA2 inhibitors. 
Both compounds were analyzed by HPLC for purity (Fig. 2). For this, all 
peaks in the chromatogram were taken for area integration using an integrated 
HPLC software. The purities were determined as 97 % for AVX001 and 92.7 % 
for AVX002. Both compounds were stored at -80°C at a 20 mM stock solution 
in DMSO under argon gas to minimize oxidation. 
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4.2.2. Cell culture  
Rat renal mesangial cells were isolated, characterized, and cultured as 
previously described [13]. For the experiments performed in this study, cells 
between passages 8-30 were used. 
 
 
 
 
 
 
 
 
 
 
Fig. 2. HPLC profiles of AVX001 and AVX002. The peak at 4.924 min (left panel) 
corresponds to AVX001. The peak at 4.599 min (right panel) corresponds to AVX002. 
 
4.2.3. In vitro cPLA2 activity assay  
Recombinant human cPLA2 enzyme was used for an in vitro activity 
assay as described by Wijkander et al [14] with some modifications according 
to Lucas and Dennis [15]. Enzyme with inhibitor (in DMSO, final concentration 
1 %) or solvent alone was preincubated in assay buffer (1 mM EDTA, 80 mM 
KCl and 10 mM HEPES (pH 7.4) containing 1.56 mM CaCl2, and 2.36 mM 
dithiothreitol for 80 sec at 37°C and 10 min at 23°C. Lipid vesicles were 
prepared by drying 4.2 nmol of L-α-1-palmitoyl-2-arachidonyl-[arachidonyl-1-
14C]-phosphatidylcholine under a stream of nitrogen. Dried lipids were 
resuspended in 2 ml assay buffer and sonicated twice for 7 min (setting: output 
3.5 and 50 % duty cycles) in a Branson Sonifier 250 (Branson Ultrasonic 
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Corporation, Danbury, CT). Sonicated lipid vesicles were added to the reaction 
to a final concentration of 0.2 µM. The reaction mixture was incubated for one 
hour at 37°C and stopped by addition of 1.7 ml chloroform/methanol/37%  KCl/ 
0.45M BHT/ 0.33M AA (2:1:0.01:0.015:0.005, by vol). After phase separation 
the lower phase was transferred to a glass tube, dried under nitrogen, and 
resuspended in chloroform/methanol (9:1, vol vol-1) and applied to a silicagel 
thin layer chromatography. Free [1-14C] arachidonic acid and L-ȕ-1-palmitoyl-
2-arachidonyl-[arachidonyl-1-14C] phosphatidylcholine (Perkin Elmer) were 
separated and analysed as described by Anthonsen et al [16].    
4.2.4. PGE2 determination  
Confluent mesangial cells in 24 well plates were pretreated for 90 min in 
the presence or absence of the inhibitors prior to stimulation for 24 h in a 
volume of 0.5 ml with IL-1ȕ (1 nM) to induce PGE2 formation. Thereafter, 
equal volumes of supernatants were subjected to a PGE2-ELISA according to 
the manufacturer’s instructions. Data were calculated as pg of PGE2 per 1.3 x 
105 cells which was the cell number per well.  
4.2.5. Cell stimulation and Western blot analysis 
 Confluent mesangial cells were stimulated as indicated in the figure 
legends in Dulbecco’s modified Eagle medium (DMEM) supplemented with 0.1 
mg ml-1 of fatty acid-free bovine serum albumin and 10 mM HEPES.  After 
stimulation, the supernatant was taken for detection of secreted IIA-sPLA2. The 
cell monolayers were homogenized in lysis buffer and processed exactly as 
previously described [17]. Cell lysates were taken for protein determination. 
Lysates containing 60 µg of protein, were separated by sodium dodecylsulfate-
polyacrylamide gel electrophoresis (SDS-PAGE), transferred to nitrocellulose 
membranes and subjected for Western blot analysis using antibodies as 
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indicated in the figure legends. Bands were detected by enhanced 
chemiluminescence method as recommended by the manufacturer. 
4.2.6. Detection of secreted IIA-sPLA2  
Equal volumes of supernatants derived from the same number of cells 
were taken for protein precipitation using 7 % (w vol-1) of trichloroacetic acid. 
Precipitated proteins were redissolved in SDS-Laemmli buffer without 
dithiothreitol and subjected to SDS-PAGE (15 % acrylamide gel), transferred to 
nitrocellulose membranes and immunostained by using a monoclonal antibody 
against rat IIA-sPLA2 at a dilution of 1:60 in 0.01 % milk powder containing 
PBS as previously described [18]. GAPDH was stained and densitometrically 
evaluated in the corresponding cell lysates and used for normalization by 
calculating the ratio between secreted sPLA2 and cytosolic GAPDH for each 
sample. 
4.2.7. Quantitative PCR analysis  
2 µg of total RNA were used for reverse transcriptase (RT)-PCR (first 
strand cDNA synthesis kit, MBI Fermentas, St.Leon-Rot, Germany) using 
random hexamer primers for amplification. mRNA levels were determined by 
quantitative real-time PCR. The following primers were used: rat sPLA2-IIA: 
forward: GCC AAA TCT CCT GCT CTA CAA ACC, reverse: ACT GGG 
CGT CTT CCC TTT GC; 18S RNA (forward: CGA TTC CGT GGG TGG 
TGG TG, reverse: CAT GCC AGA GTC TCG TTC GTT ATC); iQ™ SYBR 
Green Supermix was from BIORAD. The cycling conditions were as following: 
initial activation step (95°C/3 min), followed by 40 cycles of denaturation 
(95°C/15 sec) and annealing (58°C/1 min). PCR products were detected by 
monitoring the increase in fluorescence with iCycler, iQ5 Multicolor Real-
Time PCR Detection System, BIORAD. The BIORAD iQ5 Standard Edition 
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Optical System Software Version 2.0 was used to analyze real time and end 
point fluorescence.  
4.2.8. Cell transfection and luciferase reporter gene assay 
 A 2.67 kb fragment of the rat sPLA2-IIA promoter was cloned according 
to a previous report and fused to a luciferase reporter gene [19]. Cells were 
cultured in 12-well plates and transfected with 0.3 µg of the promoter-
containing plasmid plus 0.03 µg of a plasmid containing the renilla luciferase 
gene by using Effectene Reagent (QIAGEN, Germany) according to the 
manufacturer’s instructions. Thereafter, the transfection medium was removed 
and cells were stimulated as indicated. Values for the relative gene promoter 
activities were calculated from the ratio of firefly / renilla luciferase activities. 
4.2.9. Statistical analysis 
 Statistical analysis was performed using one-way analysis of variance 
(ANOVA) followed by a Bonferroni's post hoc test for multiple comparisons 
(GraphPad InStat version 3.00 for Windows NT, GraphPad Software, San 
Diego, CA, USA). 
4.2.10. Chemicals  
IL-1 was from Cell Concept GmbH, Umkirch, Deutschland; hyperfilm 
MP and horseradish-coupled secondary antibodies were from GE Healthcare 
Systems, Freiburg, Germany; AACOCF3, DHA, and the PPARȖ antagonist 
G3335  were from Merck Biosciences, Schwalbach, Germany; the monoclonal 
antibody against rat IIA-sPLA2 was generated and characterized as previously 
described [20]; the IκB-α antibody was from Cell Signalling, Frankfurt am 
Main, Germany; the PGE2 enzyme-linked immunosorbent assay (ELISA) was 
from Assay Designs, BIOTREND Chemikalien GmbH, Köln, Germany; all cell 
culture nutrients were from Invitrogen/Life Technologies, Karlsruhe, Germany.  
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4.3. Results 
4.3.1. AVX001 and AVX002 inhibit in vitro cPLA2 activity and reduce 
cytokine-stimulated PGE2 formation in rat renal mesangial cells 
Previously, it was shown that the ω6-PUFA derivatives arachidonyl-
trifluoromethyl ketone (AACOCF3, ATK; Fig. 1) [21] and methyl-arachidonyl 
fluorophosphonate (MAFP; Fig. 1) [22] are direct inhibitors of the group IVA 
cPLA2 in vitro. In the present study, we tested the ability of AVX001 and 
AVX002 to inhibit cPLA2 activity. In these compounds the methylene group ȕ 
to the carbonyl group of the ketone in AACOCF3 was replaced by a sulphur 
atom. Holmeide and Skattebol  speculated that this would make the carbonyl 
carbon more electrophilic and consequently the molecule a more potent 
inhibitor of cPLA2 [12]. The purity of these compounds were analyzed by 
HPLC separation (Fig. 2) and determined to be 97 % for AVX001 and 92.7 % 
for AVX002. In vitro activity assays revealed that AVX001 blocked cPLA2 
activity in a concentration-dependent manner (Fig. 3). Multiple experiments 
were taken for the determination of the IC50 value which was calculated as 120 
± 58 nM (n=28). The structurally similar compound AVX002 also blocked 
cPLA2 activity in vitro (Fig. 3). The IC50 value was analysed from several 
experiments to be 126 ± 37 nM (n=14). By comparison, AACOCF3 was a less 
potent inhibitor; it showed 30 % inhibition at 0.3 μM and 72 % inhibition at 
1μM. In contrast, the ω3-fatty acid docosahexaenoic acid (DHA) had no direct 
inhibitory effect on cPLA2 (Fig. 3). These data suggest that not only ω6-PUFA 
derivatives, but also certain ω3-PUFA derivatives, such as AVX001 and 
AVX002, but not DHA, are effective direct cPLA2 inhibitors.  
To further test the effectiveness of AVX001 and AVX002 in a cell culture 
system, rat renal mesangial cells were used which represent a good model 
system to investigate molecular inflammatory mechanisms [2]. Treatment of 
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mesangial cells with IL-1ȕ led to a high production of PGE2 confirming many 
previous reports of our group [8,23,24]. 
 
 
 
 
 
 
 
 
 
 
 
Fig.3: Direct inhibiting effect of AVX001, AVX002, ATK and DHA on cPLA2 activity in vitro. 
Recombinant cPLA2 enzyme was incubated with either solvent (DMSO, final concentration 1 %, 0) or 
the indicated concentrations of AVX001 (closed bars) or AVX002 (open bars), AACOCF3 (hatched 
bars), and DHA (dotted bars) and taken for an in vitro activity assay as described in the Methods 
Section. cPLA2 enzyme activity is given as % of control value (activity in the absence of inhibitors). 
The results shown are representative of at least three independent experiments, and data represent 
mean of duplicate determinations.  
 
The average amount of  PGE2 in different experiments varied from 0-55 
pg per 1.3 x 105 cells in unstimulated cells, to 2359-3751 pg per 1.3 x 105 cells 
in IL-1ȕ-stimulated cells. Due to this variability which seemed to depend on the 
cell passages, the maximal IL-1ȕ-stimulated values were always set to 100 %. 
In the presence of AVX001, PGE2 formation was concentration-dependently 
reduced with a 90 % inhibition at 10 μM of concentration (Fig. 4). A similar 
inhibitory effect was also seen for AVX002 (Fig. 4).  AACOCF3 also reduced 
PGE2 levels but was less potent, and docosahexaenoic acid (DHA) even at 20 
μM had no significant effect (Fig. 4). 
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Fig. 4: Effect of AVX001 and AVX002 on IL-1ȕ-stimulated PGE2 formation in mesangial cells. 
Quiescent cells were stimulated for 24 h with either DMEM (-), and IL-1ȕ (1 nM) in the absence (-) 
or presence of the indicated concentrations (in μM) of AVX001, AVX00β, AACOCF3, and 
docosahexaenoic acid (DHA). The inhibitors were all pretreated for 90 min prior to stimulation. 
Supernatants were collected and taken for PGE2 quantification by using an ELISA. Data are expressed 
as % of maximal IL-1ȕ-stimulated PGE2 and are means  S.D. (n=3).***p<0.001 considered 
statistically significant when compared to the control values; #p<0.05, ###p<0.001 when compared to 
the IL-1ȕ-stimulated values. 
 
Since we previously showed that the cytokine-induced PGE2 formation in 
mesangial cells involves both sPLA2 and cPLA2 activation [8], we then 
investigated the effect of AVX001 on sPLA2 protein and mRNA expressions. 
As seen in Fig. 5A, AVX001 and AVX002 both concentration-dependently 
down-regulated the sPLA2 protein expression paralleling the reduced PGE2 
formation. To verify that supernatants derived from equal cell amounts, 
corresponding cell monolayers were lysed and stained for GAPDH protein 
expression (Fig. 5A, inset, lower panels) and used for normalization of secreted 
proteins. A similar reducing effect on sPLA2 protein expression was also seen 
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for AACOCF3, whereas DHA had no significant effect (Fig. 5A). IIA-sPLA2 
mRNA expression was also reduced by AVX001 and AVX002 (Fig. 5B). 
Again, AACOCF3 was less potent and DHA was ineffective in reducing IIA-
sPLA2 mRNA expression (Fig. 5B). Notably, higher concentrations of AVX001 
and AVX002 were needed to down-regulate the sPLA2 protein and mRNA 
expressions compared to the reduction of PGE2.  
To see whether this effect on sPLA2 protein and mRNA expression was 
due to a reducing effect on sPLA2 promoter activation and subsequent gene 
transcription, luciferase reporter gene assays were performed. A 2.26 kb 
fragment of the rat IIA-sPLA2 promoter was cloned according to Scholz-
Pedretti et al. (2002) and ligated into a luciferase-containing vector (pGL3) and 
used to transfect mesangial cells [19]. AVX001 and AVX002 at 20 μM 
significantly reduced IL-1ȕ-stimulated promoter activity (Fig. 5C) suggesting 
that cPLA2-regulated transcription factors are essential for sPLA2 gene 
transcription.  
4.3.2. AVX inhibitors block cytokine-stimulated NFκB activity in 
mesangial cells. 
Since it is well known that the transcription factor NFκB is crucially 
involved in sPLA2 gene transcription under inflammatory conditions [25] we 
further studied whether the AVX inhibitors had an effect on NFκB activation. 
NFκB activation was measured indirectly by Western blot analysis of the 
inhibitor of κB (IκB) protein expression. Short-term stimulation of cells for 15 
min with IL-1ȕ revealed a pronounced degradation of IκB protein (Fig. 6) 
which is a key event in NFκB activation that releases NFκB from its 
sequestration in the cytoplasm and allows its nuclear translocation. This 
downregulating effect of IL-1ȕ on IκB was reverted by the IκB inhibitor Bay11-
7085, but also by AVX001 and AVX002 (Fig. 6). 
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Fig. 5: Effect of AVX001 and AVX002 on IL-1ȕ-stimulated sPLA2 protein (A), mRNA 
expression (B), and promoter activity (C) in mesangial cells. Quiescent cells were stimulated with 
either DMEM (-), or IL-1ȕ (1 nM) in the absence (-) or presence of the indicated concentrations of 
AVX001, AVX002, AACOCF3, and DHA (all inhibitors were pretreated for 90 min prior to 
stimulation. (A) Supernatants were taken for protein precipitation, separation by SDS-PAGE, transfer 
to membranes, and Western blot analysis using a monoclonal antibody against rat sPLA2. 
Corresponding cell lysates were stained for GAPDH and used for normalization. Bands were 
densitometrically evaluated and the ratio between secreted sPLA2 and cytosolic GAPDH was 
calculated. Results are expressed as % of IL-1ȕ stimulation. Data are means ± S.D. (n=γ-5). The inset 
shows representative Western blots of sPLA2 (upper panels) from supernatants (SN) and GAPDH 
(lower panels) from cell lysates. (B) Cells were taken for RNA extraction and subjected to 
quantitative PCR analysis of rat IIA-sPLA2 and 18S RNA. Δ Δ Ct values were calculated and results 
are expressed as % of maximal IL-1ȕ-stimulated response and are means  S.D. (n=3-5). (C) Cells 
were transfected with the sPLA2 promoter construct plus a plasmid coding for the Renilla luciferase. 
After transfection, cells were stimulated for 24 h with vehicle (-), IL-1ȕ (1 nM), or IL-1ȕ in the 
absence or presence of AVX001 or AVX002 (both at 20 μM). Both inhibitors were preincubated for 
90 min prior to stimulation. sPLA2 promoter activity was calculated and results are expressed as 
relative luciferase units (RLU) and are means  S.D. (n=3). **p<0.01, ***p<0.001 considered 
statistically significant when compared to the control values; #p<0.05,  ##p<0.01,  ###p<0.001 when 
compared to the IL-1ȕ-stimulated values. 
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4.3.3. AVX001 and AVX002 do not act through PPARγ activation. 
Since AVX001 and AVX002 are structurally derived from ω3-fatty acids, 
and it has been reported previously that ω3-polyunsaturated fatty acids are 
ligands and activators of peroxisome proliferator-activated receptors (PPAR) 
[26], which have been attributed an anti-inflammatory effect [27], we further 
tested whether the reducing effect of AVX compounds on PGE2 are mediated 
through PPARȖ activation. Indeed, we found that in the presence of the PPARȖ 
antagonist G3335, the AVX001 and AVX002 effects are partially reverted (Fig. 
7). However, also the IL-1ȕ effect was increased to the same extent in the 
presence of G3335 (Fig. 7) supporting the conclusion that there is rather a 
general stimulating effect of the PPARȖ antagonist on the PGE2 pathway than a 
specific antagonistic effect on the AVX action.  
 
 
 
 
 
 
 
 
Fig. 6: Effect of AVX inhibitors on IL-1ȕ-stimulated NFκB activation in mesangial cells. 
Quiescent cells were stimulated for 15min with either vehicle (Co), or IL-1ȕ (1 nM) in the absence (-) 
or presence of Bay11-7085 (Bay, 10 μM), AVX001 or AVX00β (both at γ0 μM). Thereafter, cell 
lysates were separated by SDS-PAGE, transferred to nitrocellulose and subjected to a Western blot 
analysis using a polyclonal antibody against IκBα (inset, upper panel) and GAPDH (inset, lower 
panel). Bands corresponding to IκB and GAPDH were densitometrically evaluated and the ratio 
between IκB and GAPDH was calculated for each sample. Results are depicted as % of control 
stimulations and are means  S.D. (n=3). ***p<0.001 considered statistically significant when 
compared to the control values; #p<0.05, ##p<0.01, ###p<0.001 when compared to the IL-1ȕ-stimulated 
values. The inset shows a representative experiment in duplicates. 
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4.4. Discussion 
In the last years, ω3-PUFAs have attracted a lot of interest due to 
accumulating evidence for their beneficial effects in various inflammatory 
diseases. These include rheumatoid arthritis, asthma, colitis, atherosclerosis, 
neurodegenerative diseases, and even certain forms of cancer [28–30]. 
 Various possibilities for the mechanism of these anti-inflammatory 
effects were forwarded. For example, an increased incorporation of ω3-PUFA 
species into phospholipids may occur at the expense of arachidonic acid. 
Consequently, they replace arachidonic acid as a substrate for cyclooxygenases 
and lipoxygenases resulting in reduced formation of PGE2 [31], TXA2 [32], 
LTB4 and LTE4 [33]. Instead, an increased generation of other less active 
prostaglandin and leukotriene subspecies occurs [31,32,34]. Furthermore, it was 
proposed that ω3-PUFA may change the membrane lipid composition and 
thereby directly affect the functions of immune cells including the phagocytotic 
activity of macrophages, T cell signalling and proliferation, and antigen 
presentation activity of dendritic cells [35–37].  
Various previous studies have shown that ω3-PUFAs are able to down-
regulate the gene transcription of pro-inflammatory and growth promoting 
genes by interfering with transcription factors. In this view, Liu et al. showed 
that in a mouse epidermal cell system, ω3-PUFAs, but not the ω6-arachidonic 
acid, efficiently inhibited growth factor-triggered activator protein-1 
transactivation [38]. Moreover, ω3-PUFAs downregulated cytokine-triggered 
NFκB activation and subsequent gene transcription in endothelial cells [39] as 
well as in macrophages [40]. However, in none of these studies the direct PUFA 
target was addressed. 
Intriguingly, it was recently shown that ω3-PUFAs can act as ligands of 
peroxisome proliferator-activated receptors (PPARs) and thereby can modulate 
a multitude of pro- and anti-inflammatory genes [26,41,42]. In fact, the 
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appreciated lipid-lowering effect of fish oil supplementation [43] is mainly 
explained by the action of ω3-PUFAs or metabolites as PPAR agonists [41,44]. 
ω3-PUFAs can also act as ligands for the orphan receptor GPR120 and it was 
shown that this action contributes to anti-inflammatory and insulin-sensitizing 
effects in macrophages [45]. 
 
 
 
 
 
 
 
 
 
 
 
Fig. 7: Effect of the PPARȖ antagonist Gγγγ5 on AVX001 and AVX00β reduced PGE2 
formation in mesangial cells. Quiescent cells were stimulated for 24 h with either DMEM (-), and 
IL-1ȕ (1 nM) in the absence (-) or presence of γ0 μM AVX001 or AVX00β, in the absence or 
presence of 10 μM of Gγγγ5. The inhibitors were all pretreated for 90 min prior to stimulation. 
Supernatants were collected and taken for PGE2 quantification by using an ELISA. Data are expressed 
as % of maximal IL-1ȕ-stimulated PGE2 and are means  S.D. (n=3).***p<0.001 considered 
statistically significant when compared to the control values; #p<0.05, ###p<0.001 when compared to 
the IL-1ȕ-stimulated values; §p<0.05 when compared to the corresponding AVX001 or AVX002 
values. 
 
Our data now clearly show that certain ω3-PUFA derivatives, such as 
AVX001 and AVX002, can also directly inhibit cPLA2 in vitro as well as in 
intact cells. As a consequence, they are able to downregulate cytokine-
stimulated PGE2 formation in mesangial cells and thereby reduce an 
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inflammatory reaction. Mechanistically, we could further show that cPLA2 is 
involved in crossregulation of sPLA2-IIA and iNOS expressions via NFκB 
activation. This is stressed by our findings that the direct cPLA2 inhibitors 
AVX001 and AVX002 not only down-regulated cytokine-induced sPLA2 
promoter activities (Fig. 5C), mRNA expression (Fig. 5B), protein expression 
(Fig. 5A) and subsequent activity (Fig. 4), but also, as a more upstream event, 
blocked IκB degradation and subsequent NFκB activation (Fig. 6). Notably, 
higher concentrations of AVX001 and AVX002 were needed to down-regulate 
the sPLA2 protein and mRNA expressions compared to the reduction of PGE2. 
The more potent effect on PGE2 formation than on sPLA2 expression may be 
derived from the dual action of AVX compounds, i.e. the direct inhibition of 
cPLA2 (this enzyme accounts for approx. 20% of the cytokine-induced PGE2 
formation according to Pfeilschifter et al. [8]), and the partial down-regulation 
of sPLA2 expression (this enzyme accounts for the remaining 80% of cytokine-
induced PGE2 formation according to Pfeilschifter et al. [8]). 
It is also worth noting that we previously reported that in the human 
keratinocyte cell line HaCaT, three previously known cPLA2 inhibitors, i.e. 
AACOCF3, MAFP, and the trifluoromethyl ketone analogue of EPA 
(EPACOCF3) all inhibited TNFα-induced NFκB activation and ICAM-1 
expression [46]. The reduced NFκB activity could be reversed by addition of an 
excess of exogenous arachidonic acid [16], which further underlined the 
involvement of cPLA2 in NFκB activation. Additional evidence that cPLA2 is 
positively regulating NFκB activation was also presented by Camandola et al. 
[47]. These authors showed that in promonocytic U937 cells, arachidonic acid 
stimulated NFκB activation by a mechanism involving a metabolization of 
arachidonic acid to PGs and LTs. 
However, when considering the fact that ω3-PUFAs can act as PPAR 
agonists, and the fact that the IIA-sPLA2 gene contains functional PPAR 
binding elements (PPRE) in its promoter sequence [19], and in view of the 
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recent report that parts of the anti-inflammatory effect of PPARs may be 
mediated by direct negative interference with transcription factors such as 
NFκB, AP-1 and C/EBP [48], it may have been possible that the observed 
reducing effect of the AVX compounds on PGE2 formation reported in this 
study also involves additional mechanisms besides the direct inhibition of 
cPLA2 such as PPAR activation. We have therefore used a PPARȖ antagonist to 
see whether the AVX001- and AVX002-mediated effects on PGE2 could be 
reversed. Indeed, the down-regulated PGE2 formation was increased in the 
presence of a PPARȖ antagonist (Fig. 7). However, since also the IL-1ȕ-
triggered PGE2 formation is increased by the PPARȖ antagonist, we concluded 
that there is more a general PGE2 stimulating effect by PPARȖ antagonism than 
a specific effect on AVX action. 
PLA2 activation is the rate-limiting step in the generation of eicosanoids. 
It is also the initial step in the generation of PAF which is a further potent 
inflammatory mediator. Therefore, the pharmacological inhibition of PLA2 is 
considered an attractive target to block inflammatory processes and should, at 
least theoretically, be a more effective approach than blocking one of the 
downstream enzymes like the cyclooxygenases. Unfortunately, the development 
of PLA2 inhibitors has been hampered by the fact that too many subtypes of 
PLA2 exist that are involved in a redundant manner in the inflammatory reaction 
[49–51].  
Very few PLA2 inhibitors have been developed which also exerted in 
vivo efficacy in various inflammatory animal models (reviewed in Huwiler and 
Pfeilschifter [52]). These include an inhibitor of IIA-sPLA2, LY311727 [53], 
which proved efficient in a rat model of inflammatory pain [54]. The synthesis 
of novel IIA-sPLA2 inhibitors has recently been described, which also exerted 
in vivo activity and reduced carrageenan-induced edema formation in rats with 
a similar potency as indomethacin at the dose of 10 mg kg-1 [55]. 
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Also the cPLA2 inhibitors MAFP and AACOCF3 were shown to reduce 
thermal hyperalgesia induced by carrageenan- or formalin-induced flinching in 
rats [56] suggesting that not only the IIA-sPLA2, but also the cPLA2, is involved 
in the molecular mechanisms of nociception. Furthermore, it was shown that 
AACOCF3 reduced chronic inflammatory responses in mice. Thus, AACOCF3 
given intraperitoneally inhibited phorbol ester-induced chronic ear edema [57]. 
Oral application of AACOCF3 also prevented the development of airway 
hyperresponsiveness in a mouse asthma model [57] and reduced acute lung 
injury induced by septic syndrome in mice [58]. AACOCF3 also had beneficial 
effects in a mouse model of experimental autoimmune encephalomyelitis, 
which is an inflammatory demyelinating disease of the central nervous system 
that results in central nervous system lesions [59]. However, due to the fact that 
AACOCF3 is not exclusively selective for the cPLA2 [60] and, additionally, a 
cell lytic activity has been reported [61], the various in vivo activities of 
AACOCF3 must be viewed with caution. Recently, second generation cPLA2 
inhibitors have become available such as 2-oxoamides which exerted potent 
cPLA2 inhibitory effects in vitro and proved efficiency in first in vivo models of 
inflammation and pain [62]. All these data strongly suggest that cPLA2 is a 
valid target to treat inflammatory diseases, and therefore, the development of 
novel more selective cPLA2 inhibitors is of utmost importance.  
AACOCF3 has the characteristic of being a slow binding inhibitor of 
cPLA2 [21]. The trifluoromethyl ketone group turned out to be especially 
important for inhibition since substitution of this group by either CONH2, CHO, 
COCH3 or CH(OH)CF3 led to a loss of inhibitory potency [21]. Holmeide and 
Skattebol speculated that the replacement of the methylene group ȕ to the 
carbonyl group of the ketone with a sulphur atom would make the carbonyl 
carbon more electrophilic and consequently the molecule a more potent 
inhibitor of cPLA2 [12]. This assumption is indeed confirmed by our study that 
showed a more potent inhibitory effect of the sulphur-containing AVX001 and 
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AVX002 when compared to the AACOCF3 which originally was reported to 
inhibit cPLA2 by 78 % at 1.6 mol % of AACOCF3 in the cPLA2 assay system 
[63]. A further point that needs attention is the difference of potencies of 
AVX001 and AVX002 in a cell-free in vitro system compared to the potencies 
in a cellular system. Riendeau et al. already highlighted the issue that in a 
cellular system higher concentrations of AACOCF3 were needed when 
compared to the in vitro system [63]. This is due to the fact that AACOCF3 is a 
slow binding inhibitor of cPLA2 meaning that it takes many minutes to exert its 
full inhibitory potency [21]. Since arachidonic acid release in cells is a rapid 
process taking place within minutes, relatively high concentrations are required 
to inhibit cPLA2. A second point concerns its stability. Riendeau et al. showed 
the conversion of the ketone of AACOCF3 to its non-inhibitory alcohol in cells 
which may especially become relevant in long-term stimulation settings and 
could reduce their inhibitory potential [63]. Furthermore, polyunsaturated fatty 
acids are known to be easily oxidized which can additionally reduce their 
inhibitory effect. Similar explanations may also be true for the AVX001 and 
AVX002 although the metabolism of these compounds in vivo is still unknown. 
In summary, this study has forwarded two novel cPLA2 inhibitors, i.e. the 
ω3-PUFA derivatives AVX001 and AVX002 which are efficient compounds to 
reduce inflammatory PGE2 synthesis in mesangial cells. These two compounds 
are certainly very promising candidates to be tested in in vivo disease models 
such as in models of chronic inflammatory kidney diseases. Also, further 
studies are needed to characterize the pharmacokinetic properties of these novel 
cPLA2 inhibitors AVX001 and AVX002. 
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This thesis is focused on the role of the extracellular action of S1P in 
inflammation-associated disorders, and on the determination of the S1P receptor 
subtype involved in the S1P-triggered proliferation and migration of different 
cell types including non-cancerous cells, breast cancer cells and their metastatic 
variants. In addition, we investigated the pharmacological modulation of a 
cytokine-induced inflammatory reaction in renal mesangial cells. 
Accumulating evidence has implicated altered levels of biologically 
active sphingolipids and enzymes of the sphingolipid metabolism in 
inflammatory and proliferative disorders, like glomerulonephritis, renal fibrosis, 
diabetic nephropathy and cancer [6,7]. However, there is still no definitive 
answer which molecular player in the SphK/S1P/S1PR system is the most 
favorable target for treating such diseases. In Chapter 2, the role of exogenous 
S1P and its cognate receptors in inflammation-associated breast cancer 
metastasis was studied. To investigate the contribution of S1P/S1PRs 
interaction in malignant progression of breast cancer, we used the breast cancer 
cell line MDA-MB-231 and two metastatic variants isolated from lung and bone 
metastases in athymic mice (SCP 4175 and SCP 1833, respectively). Our data 
reveal that in both metastatic sublines the basal level of S1P3 mRNA expression 
was significantly increased compared to the parental breast cancer cell line. 
Moreover, overexpression of S1P3 in metastatic cells contribute to a strong 
increase of [Ca2+]i upon stimulation with S1P, although in parental MDA-MB-
231cells the effect of S1P was marginal, which provides further evidence that 
upregulated S1P3 in metastatic cells was functionally active.  
Considering the important role of chronic inflammation in cancer 
progression, we investigated in the metastatic sublines whether eicosanoid-
derived metabolites and enzymes were altered compared to the parental cell 
population. Indeed, our data showed that the basal protein and mRNA level of 
COX-2 and mPGES1, the enzymes essential for PGE2 synthesis, were 
upregulated in lung and bone metastatic, but not in parental cells. Enhanced 
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COX-2 expression was observed in 40% of invasive breast carcinoma [26] and 
identified as a biomarker of metastasis to lung and bone [27,28]. Many human 
cancers exhibit elevated levels of PGE2 due to the upregulation of COX-2. A 
direct role of PGE2 in carcinogenesis has been shown in a number of studies. 
For instance, weekly i.p. administration of PGE2 significantly increased the 
incidence of intestinal adenomas in F344 rats [29]. In addition, another study 
demonstrated that gavage treatment of ApcMin mice with PGE2 increased 
epithelial cell proliferation and adenoma growth via the Ras/MAPK pathway 
[30]. Here, we report that exogenous S1P induces COX-2 gene expression and 
subsequent production of PGE2 in lung and bone metastatic cells, but not in 
parental MDA-MB-231 cells. Moreover, pharmacological inhibition of S1P2 
and S1P3 receptors led to a significant decrease of PGE2 secretion in the 
metastatic sublines, suggesting that both receptors are involved. On the other 
hand, the agonism of S1P3 demonstrated a critical role of this receptor subtype 
in the overproduction of PGE2 in the metastatic cells. Additionally, the synthesis 
of PGE2 in S1P3-overexpressed MDA-MB-231cells was investigated. 
According to our previous finding, the COX-2 promoter is silenced in parental 
MDA-MB-231 cell due to epigenetic modifications. Therefore, exogenous S1P 
did not exhibit any effect in S1P3-overexpressed MDA-MB-231 cells. However, 
in the presence of the demethylative agent aza-C S1P demonstrated a strong 
induction of PGE2 synthesis in S1P3 overexpressing cells compared to non-
transfected cells. These data clearly demonstrate that exogenous S1P via S1P2 
and S1P3 can induce the COX-2/ PGE2 signaling pathway in breast cancer cells.  
Cell proliferation, survival and migration represent crucial hallmarks of 
carcinogenesis and cancer progression. The S1P-mediated effect on these 
processes is determined by the pattern of receptor subtype expression. 
According to data reported by Li et al. [13], migration and invasion of Wilms 
tumor cells are mediated by S1P through the S1P1/Gi/o signaling pathway, while 
S1P2 activity rather inhibits these effects. Yamashita et al. [14] in their study 
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demonstrated that exogenous S1P stimulated migration of gastric cancer cells 
with high expression of S1P1 and/or S1P3. In contrast, migration of melanoma 
cells, which express S1P2, was inhibited by S1P [15]. Similar effects were 
observed in glioblastoma cells: cell lines expressing high level of S1P2 did not 
show enhanced migration in response to treatment with S1P [16]. Surprisingly, 
while S1P2 generally inhibits migration it can increase glioma invasiveness. 
S1P2 upregulates urokinase-type plasminogen activator (uPAR) and 
plasminogen activator inhibitor-1 (PAI-1), which are required for the invasion 
of U373 cells [17]. In prostate adenocarcinoma, S1P via S1P2 activates the Akt 
pro-survival signaling pathway [18] and S1P2 expression in chronic myeloid 
leukemia determines the stability of the BCL-ABL1 fusion protein and as a 
result increases proliferation [19]. Furthermore, S1P2-regulated ERK1/2 
phosphorylation mediates chemotherapeutic resistance of colon cancer cells 
[20]. In this context, it should not be forgotten that S1P2 can induce the COX-2/ 
PGE2 pathway, a key mediator of cancer-associated inflammation [21].   
In lung adenocarcinoma cells S1P induces proliferation and invasion 
through S1P3-mediated expression of the epidermal growth factor receptor 
(EGFR) [22]. Estrogen receptor positive (ER+) breast cancer cell lines also 
respond to S1P via S1P3 with subsequent transactivation of the EGFR [23], and 
S1P3 expression was associated with poor prognosis and shorter patient survival 
[24]. Furthermore, in estrogen receptor negative (ER-) breast cancer cells 
migration can be initiated via S1P4 and downstream activation of the ERK1/2 
pathway [25].  
In our study we found that both metastatic sublines, which overexpress 
S1P3, demonstrated a significantly higher migratory and invasive capacity 
compared to the parental MDA-MB-231 cells. These effects could be further 
enhanced by treatment with S1P or PGE2. In addition, we observed that 
antagonism of S1P3 prevents S1P-stimulated migration and invasion of 
metastatic cells whereas S1P2 antagonism has no effect. Moreover, treatment of 
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cells with the selective COX-2 inhibitor celecoxib disrupted S1P-induced cell 
migration and invasion. Therefore, the induction of PGE2 by S1P/S1P3 
interaction contributes to the migratory and invasive phenotype of breast cancer 
cells 
To investigate the mechanism by which the S1P activated COX-2/PGE2 
pathway triggers migration and invasion of metastatic cells, the mRNA 
expression pattern of EP receptors in these cells was studied. All four known EP 
receptor subtypes are expressed in MDA-MB-231 cells and its lung and bone 
metastatic sublines. However, particularly EP2 demonstrated high expression 
and was strongly upregulated in metastatic cells. Using subtype-specific EP 
receptor antagonists we identified that both the EP2 and the EP4 receptors are 
involved in S1P-triggered migration and invasion of the metastatic MDA-MB-
231 breast cancer cells. Thus, for the first time we here report that upregulation 
of S1P3 in breast cancer is a potential promoter of metastasis, which increases 
cell migration and invasion by linking S1P to the COX-2/PGE2 pathway and 
subsequent EP2/EP4 receptor activation. 
An effect of S1P on inflammation and cell migration may have impact 
not only on cancer progression and metastasis, but also for renal diseases where 
inflammation and migration are typical features for mesangioproliferative 
glomerulonephritis. To this end, our next study focused on the role of 
sphingolipids in proliferation and migration of mouse mesangial cells and 
fibroblasts. The data demonstrated in Chapter 3 reveal that cells isolated from 
SphK2 gene deficient mice as well as cells which were transiently transfected 
with siRNA against SphK2 are able to proliferate and migrate significantly 
faster when compared with the corresponding wild-type cells. This supports our 
previous finding that SphK2 has a pro-apoptotic and anti-proliferative functions 
[8]. Furthermore, we showed that the classical MAPK/ERK and PI3K/Akt 
signaling cascades are involved in the enhanced proliferative and migratory 
capacity of SphK2ko cells. The role of small G proteins in cell survival and 
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migration has been previously described [9]. To this end, here we investigated 
whether some members of the G protein family are also altered upon loss of 
SphK2. Indeed, using G-LISA® assay, we found that both the basal and S1P-
stimulated RhoA activity were significantly increased in SphK2ko mesangial 
cells, while other small G proteins (Ras, Rac and cdc42) were not affected by 
depletion of SphK2.  
Moreover, SphK2 deficiency contributes to the enhanced expression of 
SphK1, which suggests that the compensatory mechanism exist between these 
two kinases. However, quantification of sphingolipids by LC MS/MS analysis 
indicated an increase of cellular S1P only in SphK2ko MEFs but not in mMCs, 
which could be due to the higher activity of S1P transporters in mMCs and 
thereby to the faster secretion of intracellular S1P.  
Numerous studies have addressed the possible role of different S1PR 
subtypes in cell motility and migration. Katsume et al. [10] demonstrated that 
S1P mediates proliferation of mesangial cells via S1P2 and S1P3 in a Gi-
dependent manner by activation of the ERK1/2 pathway. This finding was 
supported by another study where the authors also reported on the proliferative 
capacity of exogenous S1P via S1PRs [11]. Moreover, it has been shown that 
exogenous S1P, by activating its cognate receptors, induces migration of 
mesangial cells [12]. To address this, we screened the S1PRs mRNA profile in 
SphK2ko and wild-type cells. Specifically, S1P3 expression was up-regulated in 
SphK2ko mMCs and MEFs. Furthermore, depletion of S1P3 in mMCs 
decreased cell proliferation and migration. Therefore, our study demonstrate 
that SphK2 has a suppressive effect on cell proliferation and migration, the key 
cellular responses implicated in chronic kidney inflammatory diseases. At the 
same time, suppression of SphK2 leads to an increase of S1P3 expression, which 
favors the possibility that the observed enhanced proliferation and migration 
upon loss of SphK2 could be due to an autocrine loop initiated by S1P binding 
Chapter 5. Summarizing discussion  
137 
 
to S1P3. All these finding together support the conclusion that S1P3 is involved 
in S1P stimulated cell migration/invasion in different cell types. 
Finally, in Chapter 4 the inhibitory effect of the ωγ-PUFA derivatives 
AVX001 and AVX002 on cPLA2 activity in renal mesangial cells was studied. 
Since, activation of PLA2 represents a crucial step in the generation of 
eicosanoids and, thereby, in inflammatory responses, targeting of this initial 
reaction represents a promising approach for anti-inflammatory therapy. 
Although all PLA2 isoenyzmes are able to mediate inflammation, the majority 
of evidences attribute this activity to sPLA2 and cPLA2 [1]. Particularly, sPLA2 
is speculated to be involved in general inflammatory responses, while cPLA2 is 
more associated with chronic inflammation [2]. The present study shows that 
the novel ωγ-PUFA derivatives AVX001 and AVX002 directly inhibit cPLA2 
activity in vitro and as a functional consequence efficiently reduce cytokine-
stimulated PGE2 production at low μM concentrations. Previously, Pfeilschifter 
et al. [3] demonstrated that sPLA2 and cPLA2 isoforms are both involved in 
cytokine-induced PGE2 formation. Our data suggest that AVX001 and AVX002 
reduce cytokine-stimulated sPLA2 protein and mRNA expression, as well as 
down-regulate the promoter activity of sPLA2. However, the inhibitory activity 
of AVX001 and AVX002 compounds on sPLA2 was less potent than the one 
observed on PGE2 formation, which could be due to the overlapping and more 
efficient effect on cPLA2. Mechanistically, we could further demonstrate that 
cPLA2 is involved in the cross-regulation of sPLA2 expression via NFκB 
activation. Previous studies also suggested that cPLA2 is involved in NFκB 
activation [4], in addition, NFκB is involved in sPLA2 gene transcription [5]. 
Here, we report that inhibition of cPLA2 by AVX compounds prevents NFκB 
activation by blocking IκB degradation. Also, in our study we could exclude the 
action of AVX001 and AVX002 through PPAR activation. We demonstrate 
that, although AVX-inhibited PGE2 production was partially reversed by the 
PPARȖ antagonist G3335, an even more potent effect of PPAR antagonism was 
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observed in the absence of the AVX compounds. This supports the conclusion 
that the stimulatory effect of the PPARȖ antagonist on the PGE2 pathway is 
rather general than AVX-specific. Summarizing these data, direct inhibition of 
cPLA2 activity by the novel ωγ-PUFA derivatives AVX001 and AVX002 leads 
to the consequent abrogation of PGE2 formation, suggesting that their use holds 
promising for treating inflammatory diseases.  
A summary of the S1P-induced effect on the inflammatory response in 
cells and the induction of proliferation and migration is depicted in Fig. 1. 
 
 
 
 
 
 
 
 
 
 
Fig. 1. Schematic overview of signaling pathways initiated by extracellular S1P 
(eS1P) via its cognate receptors that cause the inflammatory response and subsequent 
induction of cell proliferation and migration.  
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Conclusions and perspectives 
The work presented in this thesis expand our knowledge about the role of 
S1P in regulating inflammation and proliferation of cells implicated in the 
pathogenesis of different inflammatory disorders, including fibrosis and cancer. 
Another aspect of this work was to identify possible targets for pharmacological 
intervention to treat these diseases. Here we propose different approaches and 
several possible molecular targets to design more effective treatments. 
A major conclusion of this thesis is that S1P3 receptor upregulation 
contributes to the enhanced proliferative and migratory capacity of mesangial 
cells and embryonic fibroblasts, as well as to S1P-induced inflammation and 
subsequent increase of the metastatic potential of breast cancer cells. These 
findings confirm the concept that S1P-mediated cellular responses depend on 
the S1PR expression pattern. Here we found that the S1P3 receptor is not the 
only family member which involved in inflammatory responses mediated by 
S1P. Our data obtained in metastatic breast cancer cells clearly demonstrated 
that S1P2 activation also resulted in increased of PGE2 formation. Interestingly, 
the S1P-induced inflammatory response via S1P2 does not alter migration of 
metastatic cells. The explanation for this phenomenon could be that activation 
of S1P2 rather inhibits migration by activation of the Rho pathway. Thereby, 
this data confirms that S1P3, but not S1P2, activation by S1P contributes to 
breast cancer progression and metastasis. Moreover, the results obtained in 
studies with non-cancerous cells confirm that upregulation of S1P3 upon loss of 
SphK2 correlates with a higher proliferative and migratory capacity of cells. 
Therefore, our findings strongly suggest that the S1P/S1P3 signaling cascade 
represents a potential target for the therapeutic intervention in inflammatory-
associated renal diseases and metastatic breast cancer.  
The second major conclusion of this work is that targeting cPLA2 using 
novel PUFA inhibitors could be an effective alternative approach for preventing 
cytokine-activated inflammatory response.    
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Although, our results clearly shed more light on S1P-mediated processes 
associated with inflammatory and proliferative cellular responses, future studies 
are warranted to fully understand these processes. Future challenges include 
characterization of the specific pathophysiological role of the S1P3 receptor, as 
well as the development of more effective and specific antagonists. For 
example, preclinical studies using genetically modified mice may help to clarify 
the contribution of S1P3 to inflammation and proliferation, and to unveil the 
clinical relevance of the S1P/S1P3 signaling cascade for molecular intervention.  
.  
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